Canadian Patents Database / Patent 2557845 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 2557845
(54) English Title: PROCESS FOR PREPARING, AND COMPOSITION AND PHARMACEUTICAL DOSAGE FORMS CONTAINING, AN OXYCODONE SALT HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE
(54) French Title: COMPOSITION ET FORMULES PHARMACEUTIQUES CONTENANT UN SEL D'OXYCODONE PRESENTANT MOINS DE 25 PPM DE 14-HYDROXYCODEINONE, ET PROCEDE DE PREPARATION CONNEXE
(51) International Patent Classification (IPC):
  • C07D 489/08 (2006.01)
  • A61K 31/485 (2006.01)
  • A61P 25/04 (2006.01)
(72) Inventors :
  • CHAPMAN, ROBERT (United States of America)
  • RIDER, LONN S. (United States of America)
  • HONG, QI (United States of America)
  • KYLE, DONALD (United States of America)
  • KUPPER, ROBERT (United States of America)
(73) Owners :
  • EURO-CELTIQUE S.A. (Luxembourg)
(71) Applicants :
  • EURO-CELTIQUE S.A. (Luxembourg)
(74) Agent: GOWLING WLG (CANADA) LLP
(74) Associate agent:
(45) Issued: 2013-10-01
(86) PCT Filing Date: 2005-03-30
(87) Open to Public Inspection: 2005-10-20
Examination requested: 2006-08-25
(30) Availability of licence: N/A
(30) Language of filing: English

(30) Application Priority Data:
Application No. Country/Territory Date
60/557,492 United States of America 2004-03-30
60/601,534 United States of America 2004-08-13
60/620,072 United States of America 2004-10-18
60/648,625 United States of America 2005-01-31
60/651,778 United States of America 2005-02-10

English Abstract



In certain embodiments the invention is directed to a process for preparing an

oxycodone salt composition having less than 25 ppm of 14-hydroxycodeinone, and
to an
oxycodone salt composition and a pharmaceutical dosage form thereof, having
less than
25 ppm 14-hydroxycodeinone .


French Abstract

Dans certains modes de réalisation, l'invention concerne un procédé de préparation d'une composition d'hydrochlorure d'oxycodone présentant moins de 25 ppm de 14-hydroxycodéinone.


Note: Claims are shown in the official language in which they were submitted.

What is claimed is:
1. A process for preparing an oxycodone salt composition having less than
25 ppm 14-hydroxycodeinone, which process comprises the steps of:
(a) providing an oxycodone base composition, said oxycodone base composition
comprising an amount of 8.alpha.,14-dihydroxy-7,8-dihydrocodeinone;
(b) reacting said oxycodone base composition with an acid under conditions
suitable to convert the oxycodone base composition to an oxycodone salt
composition
and to promote an acid catalyzed dehydration of 8.alpha.,14-dihydroxy-7,8-
dihydrocodeinone
to 14-hydroxycodeinone; and
(c) reducing an amount of 14-hydroxycodeinone in the oxycodone salt
composition formed in step (b) to produce an oxycodone salt composition having
less
than 25 ppm 14-hydroxycodeinone.
2. The process of claim 1, wherein the acid is hydrochloric acid, and the
oxycodone salt is oxycodone hydrochloride.
3. The process of any one of claims 1-2, comprising a further step of
removing 8.alpha.,14-dihydroxy-7,8-dihydrocodeinone from the oxycodone base
composition
before step (b).
4. The process of any one of claims 1-3, wherein the reacting in step (b)
is
carried out in a solvent.
5. The process of any one of claims 1-4, wherein the oxycodone salt
composition formed in step (c) has less than about 15 ppm 14-hydroxycodeinone.
6. The process of any one of claims 1-4, wherein the oxycodone salt
composition formed in step (c) has less than about 10 ppm 14-hydroxycodeinone.


7. The process of any one of claims 1-4, wherein the oxycodone salt
composition formed in step (c) has less than about 5 ppm 14-hydroxycodeinone.
8. The process of any one of claims 1-6, wherein the oxycodone salt
composition formed in step (c) has lower limit of 14-hydroxycodeinone of 5
ppm.
9. The process of any one of claims 1-7, wherein the oxycodone salt
composition formed in step (c) has lower limit of 14-hydroxycodeinone of 0.25
ppm.
10. The process of any one of claims 1-7, wherein the oxycodone salt
composition formed in step (c) has lower limit of 14-hydroxycodeinone of 0.5
ppm.
11. The process of any one of claims 1-7, wherein the oxycodone salt
composition formed in step (c) has lower limit of 14-hydroxycodeinone of 1
ppm.
12. The process of any one of claims 1-7, wherein the oxycodone salt
composition formed in step (c) has lower limit of 14-hydroxycodeinone of 2
ppm.
13. The process of any one of claims 1-12, comprising the step of
hydrogenating the oxycodone salt composition formed in step (b).
14. The process of claim 13, comprising a pH adjustment step which is
performed after said hydrogenation step.
15. The process of claim 14, wherein the pH is adjusted from about 1.5 to
about 2.5.
16. The process of any one of claims 1-15, further comprising a step of
recovering the oxycodone salt composition having less than 25 ppm 14-
hydroxycodeinone.

61


17. The process of claim 16, wherein the reacting in step (b) is carried
out in a
solvent, and the recovery step comprises crystallizing the oxycodone salt
composition
having less than 25 ppm 14-hydroxycodeinone and filtering the crystallized
composition
from the solvent.
18. The process of any one of claims 1-17, wherein in step (b), the acid is

present in an amount greater than 1 molar equivalent compared to the amount of

oxycodone.
19. The process of claim 18, wherein the acid is present in an amount
greater
than about 1.2 molar equivalents compared to the amount of oxycodone.
20. The process of claim 18, wherein the acid is present in an amount
greater
than about 1.4 molar equivalents compared to the amount of oxycodone.
21. The process of claim 18, wherein the acid is present in an amount
greater
than about 1.5 molar equivalents compared to the amount of oxycodone.
22. A process for preparing an oxycodone salt composition as claimed in any

one of claims 1-21, wherein the 14-hydroxycodeinone is reduced by
hydrogenation with
hydrogenation reagents and under conditions sufficient for conversion of 14-
hydroxycodeinone to oxycodone salt.
23. The process of claim 22, wherein the hydrogenation reagents comprise a
catalyst.
24. The process of claim 22, wherein the hydrogenation reagents are a
catalyst
and a hydrogen donor.

62


25. The process of any one of claims 23-24, wherein the catalyst is
palladium
on carbon.
26. The process of claim 24, wherein the hydrogen donor is selected from
the
group consisting of hydrogen gas, formic acid, indoline, cyclohexene, sodium
borohydride, tetrahydroquinoline, 2,5-dihydrofuran, phosphoric acid, and
combinations
thereof.
27. The process of any one of claims 13 and 22-26, wherein the
hydrogenation
is carried out at a temperature of from about 20°C to about
100°C.
28. The process of claim 27, wherein the hydrogenation is carried out at a
temperature of from about 40°C to about 85°C.
29. The process of any one of claims 13 and 22-28, wherein the
hydrogenation
is carried out at a pH of less than 5 or less than 3.
30. The process of any one of claims 13 and 22-29, wherein the
hydrogenation
is carried out at a pH of less than 1.
31. The process of any one of claim 13 and claims 22-30, wherein step (c)
comprises hydrogenating the oxycodone salt composition formed in step (b), and
wherein
said oxycodone salt composition formed in step (b) has at least 100 ppm 14-
hydroxycodeinone.
32. The process of claim 31, wherein said hydrogenation is performed under
reflux.
33. The process of any one of claims 13 and 22-30, wherein the
hydrogenation
produces an oxycodone salt composition having between 15 ppm and 25 ppm 14-

63


hydroxycodeinone, and the oxycodone salt composition having between 15 ppm and
25
ppm 14-hydroxycodeinone is further hydrogenated to produce an oxycodone salt
composition having less than 10 ppm 14-hydroxycodeinone.
34. The process of any one of claims 13 and 22-30, wherein the
hydrogenation
produces an oxycodone salt composition having a 14-hydroxycodeinone level of
between
ppm and 25 ppm, and the oxycodone salt composition having between 10 ppm and
25
ppm 14-hydroxycodeinone is further hydrogenated to produce an oxycodone salt
composition having less than 5 ppm 14-hydroxycodeinone.
35. The process of any one of claims 27-34, wherein the hydrogenation is
performed without a hydrogen gas feed.
36. The process of any one of claims 13 or 22-35, wherein the hydrogenation

time is from about 10 min to about 36 hours.
37. The process of any one of claims 13 or 22-36, wherein the hydrogenation

is carried out in a solvent.
38. The process of claim 37, wherein the solvent is an alcohol.
39. The process of claim 38, wherein the alcohol is selected from the group

consisting of methanol, ethanol and isopropanol.
40. The process of claim 37, wherein the solvent is a combination of
isopropanol and water.
41. The process of any one of claims 37-40, further comprising increasing
the
pH of the solution with a basic agent after the hydrogenation.

64


42. The process of claim 41, wherein the basic agent is sodium hydroxide.
43. The process of any one of claims 41-42, wherein the pH of the solution
is
less than 1.0 and is adjusted to a pH of about 1.5 to about 2.5.
44. A process for preparing an oxycodone salt composition having less than
25 ppm 14-hydroxycodeinone as claimed in any one of claims 1-21, wherein step
(c) is
performed by contacting the oxycodone salt composition formed in step (b) with
a
substance that preferentially removes 14-hydroxycodeinone as compared to the
oxycodone salt.
45. The process of claim 44, wherein said contacting comprises passing a
solution comprising said oxycodone salt composition through said substance.
46. The process of claim 44, wherein said substance is a gel.
47. The process of claim 46, wherein said contacting comprises forming a
slurry with said oxycodone salt composition and said gel.
48. A process for preparing an oxycodone salt composition having less than
25 ppm 14-hydroxycodeinone as claimed in any one of claims 1-21, comprising:
a step of contacting the oxycodone base composition of step (a) with a
substance
that preferentially removes 8.alpha.,14-dihydroxy-7,8-dihydrocodeinone as
compared to the
oxycodone base.
49. The process of claim 48, wherein said contacting comprises passing a
solution comprising said oxycodone base composition through said substance.
50. The process of claim 48, wherein said substance is a gel.



51. The process of claim 50, wherein said contacting comprises forming a
slurry with said oxycodone base composition and said gel.
52. A process for preparing an oxycodone salt composition having less than
25 ppm 14-hydroxycodeinone as claimed in any one of claims 1-21, wherein step
(b) is
performed by titrating the oxycodone base composition of step (a) with the
acid.
53. A process for preparing an oxycodone salt composition having less than
25 ppm 14-hydroxycodeinone as claimed in any one of claims 1-21, comprising:
oxidizing a thebaine composition to form a 14-hydroxycodeinone composition,
said oxidizing being performed at a suitable pH to minimize or eliminate the
production
of 8.alpha.,14-dihydroxy-7,8-dihydrocodeinone in said 14-hydroxycodeinone
composition;
hydrogenating said 14-hydroxycodeinone composition to form an oxycodone base
composition; and
converting said oxycodone base composition to an oxycodone salt composition
having less than 25 ppm 14-hydroxycodeinone.
54. The process of claim 53, wherein the hydrogenation step is performed as

defined in any one of claims 13 or 22-43.
55. A process for preparing an oxycodone salt composition having less than
25 ppm 14-hydroxycodeinone as claimed in any one of claims 1-21, comprising:
a step of subjecting the oxycodone base composition of step (a) to
chromatographic separation to preferentially remove 8.alpha.,14-dihydroxy-7,8-
dihydrocodeinone as compared to the oxycodone base.
56. The process of claim 55, wherein said chromatographic separation is a
simulated moving bed.

66


57. A process for preparing an oxycodone salt composition having less than
25 ppm 14-hydroxycodeinone as claimed in any one of claims 1 and 3-21,
comprising:
performing step (b) by reacting the oxycodone base composition with an acid
having a higher pH than hydrochloric acid to form a corresponding acid
addition salt of
oxycodone; and
converting said acid addition salt of oxycodone to an oxycodone hydrochloride
composition having less than 25 ppm 14-hydroxycodeinone.
58. The process of claim 57, wherein said acid is selected from the group
consisting of tartaric acid, oxalic acid, fumaric acid, phosphoric acid,
sulfuric acid and
mixtures thereof.
59. A composition comprising (i) an oxycodone salt and (ii) 14-
hydroxycodeinone in an amount of less than 25 ppm.
60. The composition of claim 59, wherein at least a portion of the 14-
hydroxycodeinone is derived from 8.alpha.,14-dihydroxy-7,8-dihydrocodeinone.
61. The composition of claim 59, wherein the 14-hydroxycodeinone is solely
derived from 8.alpha.,14-dihydroxy-7,8-dihydrocodeinone.
62. The composition of any one of claims 59-61 when made by the process of
any one of claims 1-58.
63. The composition of any one of claims 59-62, wherein the oxycodone salt
is oxycodone hydrochloride.
64. The composition of any one of claims 59-63, having less than about 15
ppm 14-hydroxycodeinone.

67


65. The composition of any one of claims 59-63, having less than about 10
ppm 14-hydroxycodeinone.
66. The composition of any one of claims 59-63, having less than about 5
ppm
14-hydroxycodeinone.
67. The composition of any one of claims 59-65, having a lower limit of 14-
hydroxycodeinone of 5 ppm.
68. The composition of any one of claims 59-66, having a lower limit of 14-
hydroxycodeinone of 0.25 ppm.
69. The composition of any one of claims 59-66, having a lower limit of 14-
hydroxycodeinone of 0.5 ppm.
70. The composition of any one of claims 59-66, having a lower limit of 14-
hydroxycodeinone of 1 ppm.
71. The composition of any one of claims 59-66, having a lower limit of 14-
hydroxycodeinone of 2 ppm.
72. A pharmaceutical dosage form comprising (i) an oxycodone salt
composition comprising an oxycodone salt, and less than 25 ppm 14-
hydroxycodeinone,
and (ii) at least one excipient.
73. The pharmaceutical dosage form of claim 72, wherein said oxycodone
saltcomposition is prepared using the process as claimed in any one of claims
1-58.
74. The pharmaceutical dosage form of any one of claims 72-73, wherein the
oxycodone salt is oxycodone hydrochloride.

68


75. The pharmaceutical dosage form of any one of claims 72-74, wherein the
oxycodone salt composition has less than about 15 ppm 14-hydroxycodeinone.
76. The pharmaceutical dosage form of any one of claims 72-74, wherein the
oxycodone salt composition has less than about 10 ppm 14-hydroxycodeinone.
77. The pharmaceutical dosage form of any one of claims 72-74, wherein the
oxycodone salt composition has less than about 5 ppm 14-hydroxycodeinone.
78. The pharmaceutical dosage form of any one of claims 72-76, wherein a
lower limit of 14-hydroxycodeinone in the oxycodone salt composition is 5 ppm.
79. The pharmaceutical dosage form of any one of claims 72-77, having a
lower limit of 14-hydroxycodeinone in the oxycodone salt composition of 0.25
ppm.
80. The pharmaceutical dosage form of any one of claims 72-77, having a
lower limit of 14-hydroxycodeinone in the oxycodone salt composition of 0.5
ppm.
81. The pharmaceutical dosage form of any one of claims 72-77, having a
lower limit of 14-hydroxycodeinone in the oxycodone salt composition of 1 ppm.
82. The pharmaceutical dosage form of any one of claims 72-77, having a
lower limit of 14-hydroxycodeinone in the oxycodone salt composition of 2 ppm.
83. The pharmaceutical dosage form of any one of claims 72-82, wherein the
at least one excipient provides sustained release of the oxycodone salt.
84. The pharmaceutical dosage form of any one of claims 72-82, wherein the
at least one excipient comprises a sustained release material, and the
sustained release
material is incorporated into a matrix along with the oxycodone salt
composition.

69


85. The pharmaceutical dosage form of any one of claims 72-82, wherein the
dosage form is for oral administration and comprises from about 10 mg to about
320 mg
of the oxycodone salt composition.
86. The pharmaceutical dosage form of claim 85, in the form selected from
the group consisting of tablets, troches, lozenges, powders, granules, hard
capsules, soft
capsules, microparticles, buccal tablets, solutions and suspensions.
87. The pharmaceutical dosage form of any one of claims 85-86, which is a
sustained release oral formulation.
88. The oral pharmaceutical dosage form of claim 87 which is in the form of
a
coated tablet or a multiparticulate formulation.
89. A sustained release oral dosage form comprising particles, the
particles
comprising from about 10 mg to about 320 mg the oxycodone salt composition of
any
one of claims 59-71, said particles being film-coated with a material that
permits release
of the oxycodone salt at a sustained rate in an aqueous medium.
90. A pharmaceutical dosage form comprising (i) from about 5 mg to about
320 mg of the oxycodone salt composition of any one of claims 59-71; and (ii)
a
sustained release material, wherein the sustained release material is film
coated onto said
oxycodone salt composition.
91. A pharmaceutically acceptable package containing at least 1 kg of the
composition of any one of claims 59-71 or the dosage form as claimed in any
one of
claims 72-90.
92. The pharmaceutically acceptable package of claim 91, containing the
composition in an amount from about 10 kg to about 1000 kg.



93. The pharmaceutically acceptable package of claim 91, containing the
composition in an amount from about 10 kg to about 500 kg.
94. The pharmaceutically acceptable package of claim 91, containing the
composition in an amount from about 20 kg to about 100 kg.
95. The pharmaceutically acceptable package of claim 91, containing the
composition in an amount from about 20 kg to about 50 kg.
96. The pharmaceutically acceptable package of any one of claims 91-95,
wherein the package is selected from the group of packages consisting of a
corrugated
box container, a drum and a flexible intermediate bulk container.
97. The pharmaceutically acceptable package of any one of claims 91-96,
further comprising a liner between the package and the composition.
98. The pharmaceutical dosage form of any one of claims 85 and 90, wherein
the oxycodone salt is present in an amount of 5 mg, 10 mg, 15mg, 20 mg, 30 mg,
40 mg,
50 mg, 60 mg, 80 mg, 100 mg, 120 mg, 160 mg or 320 mg.
99. The sustained release oral dosage form of claim 89, wherein the
oxycodone salt is present in an amount of 5 mg, 10 mg, 15mg, 20 mg, 30 mg, 40
mg, 50
mg, 60 mg, 80 mg, 100 mg, 120 mg, 160 mg or 320 mg.

71

Note: Descriptions are shown in the official language in which they were submitted.

CA 02557845 2010-07-23
PROCESS FOR PREPARING, AND COMPOSITION AND PHARMACEUTICAL
DOSAGE FORMS CONTAINING, AN OXYCODONE SALT HAVING LESS
THAN 25 PPM 14-HYDROXYCODEINONE
FIELD OF THE INVENTION
[0001] The present invention relates to a process for reducing the amount of
14-
hydroxycodeinone in an oxycodone salt composition, and a composition and
pharmaceutical dosage form containing a pharmaceutically acceptable salt of
oxycodone
having less than 25 ppm 14-hydroxycodeinone.
BACKGROUND OF THE INVENTION
[00021 Oxycodone is a semi-synthetic opioid analgesic that exerts an agonist
effect at
specific, saturable opioid receptors in the CNS and other tissues. In man,
oxycodone may
produce any of a variety of effects including analgesia.
100031 Purdue Pharma L.P currently sells sustained-release oxycodone in dosage
forms
containing 10, 20, 40, and 80 mg oxycodone hydrochloride under the trade name
OxyContine.
[0004] U.S. Patent Nos. 5,266,331; 5,508,042; 5,549,912; and 5,656,295
disclose
sustained release oxycodone formulations.
100051 Thebaine, a compound derived from opium, although having no medicinal
use in
itself, is useful as a starting material in synthetic schemes for the
production of
oxycodone. In other schemes, codeine can be utilized as the starting material
for the
production of oxycodone. 14-hydroxycodeinone is the immediate precursor to
oxycodone in these schemes.
[0006] Methods of producing thebaine or 14-hydroxy substituted opium
derivatives have
been reported, e.g. in U.S. Patent No. 3,894,026 and U.S. Patent No.
4,045,440.
1

CA 02557845 2010-07-23
[0007] The oxidation of codeine to codeinone, an initial step in the synthesis
of opium
derivatives has been reported in EP 0889045, U.S. Patent No. 6,008,355 and in
the J. Am.
Chem. Soc., 1051, 73, 4001 (Findlay).
[0008] The reaction of codeinone to 14-hydroxycodeinone has been reported in
U.S.
Patent No. 6,008,355 and in Tetrahedron 55, 1999 (Coop and Rice).
[0009] The methylation of codeinone to thebaine has been reported in
Heterocycles,
1988, 49, 43-7 (Rice) and EP0889045.
[0010] U.S. Patent No. 6,177,567 describes the hydrogenation of 14-
hydroxycodeinone
to oxycodone by reduction with diphenylsilane and Pd(Ph3P)anC12 or with sodium

hypophosphite in conjunction with a Pd/C catalyst in aqueous acetic acid.
[0011] Krabnig et al. in "Optimization of the Synthesis of Oxycodone and 5-
Methyloxycodone" Arch. Phann. (1996), 329(6), (325-326) describes
hydrogenating a
solution of 14-hydroxycodeinone in glacial acetic acid with a Pd-C-catalyst at
30 psi at
the described conditions.
100121 Oxycodone hydrochloride API (active pharmaceutical ingredient) is
available
from a variety of manufacturers such as Johnson Matthey and Mallinckrodt.
Current
commercially-available oxycodone hydrochloride API, and oxycodone
hydrochloride
prepared by known procedures, have a level of 14-hydroxycodeinone of greater
than 100
ppm.
[0013] There is a continuing need in the art to provide an oxycodone salt
composition
and dosage form that contains reduced amounts of 14-hydroxycodeinone as
compared to
oxyodone salt compositions and dosage forms known in the art, and in
particular an
oxycodone hydrochloride composition and dosage form that contains reduced
amounts of
14-hydroxycodeinone as compared to known oxycodone hydrochloride compositions
and
dosage forms thereof.
2

CA 02557845 2010-07-23
OBJECTS AND SUMMARY OF THE INVENTION
10014] It is an object of certain embodiments of the present invention to
provide a
process for reducing the 14-hydroxycodeinone in an oxycodone hydrochloride
composition to an amount of less than 25 ppm, less than about 15 ppm, less
than about 10
ppm, or less than about 5 ppm.
100151 It is a further object of certain embodiments of the present invention
to provide an
oxycodone hydrochloride composition and an oxycodone hydrochloride dosage form

containing oxycodone hydrochloride having a 14-hydroxycodeinone level of less
than 25
ppm, less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm.
100161 It is an object of certain embodiments of the present invention to
provide a
process for reacting an oxycodone base composition with hydrochloric acid
under
conditions to produce an oxycodone hydrochloride composition having an amount
of 14-
hydroxycodeinone of less than 25 ppm, less than about 15 ppm, less than about
10 ppm,
or less than about 5 ppm.
100171 During the oxidation of thebaine to give 14-hydroxycodeinone, several
overoxidized products are formed including 8,14-dihydroxy-7,8-
dihydrocodeinone. In
the production of oxycodone free base from the 14-hydroxycodeinone, the 8,14-
dihydroxy-7,8-dihydrocodeinone is carried though the process. During
conversion of the
oxycodone free base to oxycodone hydrochloride, the impurity undergoes acid-
catalyzed
dehydration and is converted into 14-hydroxycodeinone. Thus, 14-
hydroxycodeinone is
present in the final oxycodone hydrochloride composition. It is thus a further
object of
certain embodiments of the present invention to provide a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less
than
25 ppm by reacting an oxycodone base composition with hydrochloric acid under
conditions suitable to promote dehydration of 8,14-dihydroxy-7,8-
dihydrocodeinone, and
in particular of 8a,14-dihydroxy-7,8-dihydrocodeinone, to 14-hydroxycodeinone
during
salt formation, and under reducing conditions so as to convert the14-
hydroxycodeinone to
oxycodone.
3

CA 02557845 2010-07-23
100181 Accordingly, in one main embodiment, the invention comprises a process
for
preparing an oxycodone salt composition having less than 25 ppm 14-
hydroxycodeinone,
which process comprises the steps of:
(a) providing an oxycodone base composition, said oxycodone base composition
comprising an amount of 8a,14-dihydroxy-7,8-dihydrocodeinone;
(b) reacting said oxycodone base composition with an acid under conditions
suitable to convert the oxycodone base composition to an oxycodone salt
composition
and to promote an acid catalyzed dehydration of 8a,14-dihydroxy-7,8-
dihydrocodeinone
to 14-hydroxycodeinone; and
(c) reducing an amount of 14-hydroxycodeinone in the oxycodone salt
composition formed in step (b) to produce an oxycodone salt composition having
less
than 25 ppm 14-hydroxycodeinone.
100191 In a preferred embodiment of the above aspect of the invention, the
acid is
hydrochloric acid, and the oxycodone salt is oxycodone hydrochloride.
[0020] In a refinement thereof, the process comprises a further step of
removing 8a,14-
dihydroxy-7,8-dihydrocodeinone from the oxycodone base composition before step
(b).
100211 In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less
than
25 ppm comprising reacting an oxycodone hydrochloride composition having a 14-
hydroxycodeinone level of more than 100 ppm under conditions that reduce the
amount
of 14-hydroxycodeinone to a level of less than 25 ppm, less than about 15 ppm,
less than
about 10 ppm, or less than about 5 ppm.
100221 In certain embodiments, the invention is directed to an oxycodone
hydrochloride
composition having a 14-hydroxycodeinone level of less than 25 ppm, less than
about 15
ppm, less than about 10 ppm, or less than about 5 ppm.
(0023] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less
than
25 ppm comprising subjecting an oxycodone hydrochloride composition having a
14-
4

CA 02557845 2010-07-23
hydroxycodeinone level of greater than 100 ppm to hydrogenation to an extent
that the
amount of 14-hydroxycodeinone in the composition is reduced to an amount of
less than
less 25 ppm, less than about 15 ppm, less than about 10 ppm, or less than
about 5 ppm.
[0024] In certain embodiments disclosed herein, the oxycodone composition
having a 14-
hydroxycodeinone level of less than 25 ppm can be subsequently hydrogenated to
further
decrease the amount of 14-hydroxycodeinone, e.g., from about 15 ppm to about
10 ppm
or less.
[0025] In one embodiment, where the starting material is an oxycodone
hydrochloride
composition comprising 14-hydroxycodeinone in an amount of 100 ppm or higher,
the
final oxycodone hydrochloride composition has a 14-hydroxycodeinone level of
less than
25 ppm, less than about 15 ppm, less than about 10 ppm, or less than about 5
ppm. In
another embodiment, where the starting material is an oxycodone hydrochloride
composition comprising 14-hydroxycodeinone in an amount of between 15 ppm and
25
ppm, the final oxycodone hydrochloride composition has a 14-hydroxycodeinone
level of
less than about 10 ppm, or less than about 5 ppm. In another embodiment, where
the
starting material is an oxycodone hydrochloride composition comprising 14-
hydroxycodeinone in an amount of between 10 ppm and 25 ppm, the final
oxycodone
hydrochloride composition has a 14-hydroxycodeinone level of less than about 5
ppm.
[0026] In certain embodiments of the present invention, the process for
preparing the
oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less
than
25 ppm comprises hydrogenating the starting material under reflux. In certain
embodiments, the process further comprises recovering the resultant oxycodone
hydrochloride composition having a 14-hydroxycodeinone level of less than 25
ppm.
[0027] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less
than
25 ppm comprising hydrogenating under reflux, a starting oxycodone
hydrochloride
composition having a 14-hydroxycodeinone level of greater than 100 ppm in a
suitable
solvent for a time sufficient to produce an oxycodone composition having a 14-
hydroxycodeinone level of less than 25 ppm, less than about 15 ppm, less than
about 10

CA 02557845 2010-07-23
ppm, or less than about 5 ppm; and recovering the oxycodone hydrochloride
composition
having a 14-hydroxycodeinone level of less than 25 ppm by crystallization and
removal
from the solvent (e.g., by filtration).
[0028] In certain embodiments, the oxycodone hydrochloride composition of the
present
invention has a lower limit of 0.25 ppm, 0.5 ppm, 1 ppm, 2 ppm or 5 ppm of 14-
hydroxycodeinone.
[0029] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level in an
amount
of less than 25 ppm comprising reacting in a suitable solvent an oxycodone
base
composition with hydrochloric acid in an amount greater than 1.0 molar
equivalent as
compared to the oxycodone base composition, the reacting step being performed
under
reducing conditions, to form an oxycodone hydrochloride composition having a
14-
hydroxycodeinone level in an amount of less than 25 ppm.
[0030] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having less than 25 ppm 14-
hydroxycodeinone
comprising hydrogenating a 14-hydroxycodeinone composition to obtain an
oxycodone
free base composition; converting the oxycodone free base composition to
oxycodone
hydrochloride; and hydrogenating the oxycodone hydrochloride to obtain an
oxycodone
composition having less than 25 ppm 14-hydroxycodeinone.
[0031] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having less than 25 ppm 14-
hydroxycodeinone
comprising hydrogenating a 14-hydroxycodeinone composition to obtain an
oxycodone
free base composition; converting the oxycodone free base composition to
oxycodone
hydrochloride; isolating the oxycodone hydrochloride; and hydrogenating the
oxycodone
hydrochloride to obtain an oxycodone composition having less than 25 ppm 14-
hydroxycodeinone.
[0032] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having less than 25 ppm 14-
hydroxycodeinone
6

CA 02557845 2010-07-23
comprising oxidizing a thebaine composition to form 14-hydroxycodeinone
composition,
the oxidizing being performed at a suitable pH to minimize or eliminate the
production of
8,14-dihydroxy-7,8-dihydrocodeinone in the 14-hydroxycodeinone composition;
hydrogenating the 14-hydroxycodeinone composition to form an oxycodone base
composition; and converting the oxycodone base composition to an oxycodone
hydrochloride composition having less than 25 ppm 14-hydroxycodeinone.
[00331 In certain embodiments, the invention is directed to a process for
preparing 14-
hydroxycodeinone comprising oxidizing a thebaine composition to form 14-
hydroxycodeinone composition, the oxidizing being performed at a suitable pH
to
minimize or eliminate the production of 8,14-dihydroxy-7,8-dihydrocodeinone in
the 14-
hydroxycodeinone composition.
100341 In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition comprising reacting an oxycodone base
composition with an acid having a higher pH than hydrochloric acid to form a
corresponding acid addition salt of oxycodone, and converting the acid
addition salt of
oxycodone to oxycodone hydrochloride.
[00351 In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level in an
amount
of less than 25 ppm comprising contacting an oxycodone base composition having
an
amount of 8,14-dihydroxy-7,8-dihydrocodeinone with a substance that
preferentially
removes the 8,14-dihydroxy-7,8-dihydrocodeinone as compared to the oxycodone
base;
and converting the oxycodone base composition to an oxycodone hydrochloride
composition having less than 25 ppm 14-hydroxycodeinone.
[00361 In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level in an
amount
of less than 25 ppm comprising subjecting an oxycodone base composition having
an
amount of 8,14-dihydroxy-7,8-dihydrocodeinone to chromatographic separation to

preferentially removes the 8,14-dihydroxy-7,8-dihydrocodeinone as compared to
the
7

CA 02557845 2010-07-23
oxycodone base; and converting the oxycodone base composition to an oxycodone
hydrochloride composition having less than 25 ppm 14-hydroxycodeinone.
[0037] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level in an
amount
of less than 25 ppm comprising reacting in a suitable solvent an oxycodone
base
composition having an amount of 8,14-dihydroxy-7,8-dihydrocodeinone, with
boronated
polystyrene resin; and converting the oxycodone base composition to an
oxycodone
hydrochloride composition having less than 25 ppm 14-hydroxycodeinone.
[0038] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition comprising reacting in a suitable solvent
an
oxycodone base composition with boronated polystyrene resin; and converting
the
oxycodone base composition to an oxycodone hydrochloride composition.
[0039] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level in an
amount
of less than 25 ppm comprising combining hydrochloric acid and an oxycodone
base
composition having an amount of 8,14-dihydroxy-7,8-dihydrocodeinone in a
solvent to
form a solution; and spray drying the solution to generate oxycodone
hydrochloride
composition having a 14-hydroxycodeinone level in an amount of less than 25
ppm.
[0040] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition having a 14-hydroxycodeinone level in an
amount
of less than 25 ppm comprising combining hydrochloric acid and an oxycodone
base
composition having an amount of 8,14-dihydroxy-7,8-dihydrocodeinone in a
solvent to
form a solution; and lyophilizing the solution to generate oxycodone
hydrochloride
composition having a 14-hydroxycodeinone level in an amount of less than 25
ppm.
[0041] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition comprising combining hydrochloric acid and
an
oxycodone base composition in a solvent to form a solution; and spray drying
the
solution to generate oxycodone hydrochloride.
8

CA 02557845 2010-07-23
[0042] In certain embodiments, the invention is directed to a process for
preparing an
oxycodone hydrochloride composition comprising combining hydrochloric acid and
an
oxycodone base composition in a solvent to form a solution; and lyophilizing
the solution
to generate oxycodone hydrochloride. The term "bulk" means an amount of
material of at
least 1 kg. In certain embodiments, the amount can be from about 10 kg to
about 1000 kg
or from about 10 kg to about 500 kg. In certain embodiments, the amount is in
an
amount of from about 20 kg to about 100 kg; about 20 kg or about 50 kg. Bulk
oxycodone hydrochloride composition can be packaged, e.g., in a
pharmaceutically
acceptable package such as corrugated box containers (made of, e.g., plastic
and/or
paper); in drums (made of, e.g., a metal or metal composite material); or in
bags of
woven fabric generally referred to as flexible intermediate bulk containers
(FIBCs). Each
of these approaches use various configurations of liners, typically made of
polyethylene
or polypropylene, that fit within the corrugated box, drum, or within the FIBC
for
preventing contamination of the product being shipped. Preferably, these
packaging
approaches use containers configured to be supported by and carried on
pallets.
[0043] In certain embodiments, the invention is directed to an oxycodone salt
composition and an oxycodone salt dosage form having less than 25 ppm 14-
hydroxycodeinone.
[0044] The term "ppm" as used herein means "parts per million". As used to
refer to 14-
hydroxycodeinone, "ppm" means parts per million of 14-hydroxycodeinone in a
particular sample.
[0045] The term 8,14-dihydroxy-7,8-dihydrocodeinone includes either 8a,14-
dihydroxy-
7,8-dihydrocodeinone; or 813,14-dihydroxy-7,8-dihydrocodeinone or can include
a
mixture of both compounds.
[0046] The oxycodone hydrochloride preparation can be, e.g., an oxycodone
active
pharmaceutical ingredient (API), such as oxycodone hydrochloride U.S.P.,
uncombined
or combined with one or more other ingredients. For example, the oxycodone
preparation can be a final pharmaceutical dosage form, or an intermediate
preparation for
a final dosage form, that can be tested for the presence of 14-
hydroxycodeinone and/or
9

CA 02557845 2010-07-23
codeinone, e.g., for quality assurance purposes. Preferably, the oxycodone
hydrochloride
preparation is oxycodone hydrochloride API and contains at least 95% oxycodone

hydrochloride, at least 98% oxycodone hydrochloride, at least 99% oxycodone
hydrochloride, or at least 99.9% oxycodone hydrochloride.
[0047] The method of detecting the presence of 14-hydroxycodeinone in an
oxycodone
preparation can be performed in accordance International Publication Number
W02005/098414.
BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 is a schematic of a reaction of thebaine to oxycodone
hydrochloride,
including the oxidation of thebaine to 14-hydroxycodeinone and an 8a,14-
dihydroxy-7,8-
dihydrocodeinone impurity.
[0049] Figure 2 is a schematic of the dehydration of the 8a,14-dihydroxy-7,8-
dihydrocodeinone to 14-hydroxycodeinone.
[0050] Figure 3 depicts a separation of the system suitability testing
solution of Example
4.
[0051] Figure 4 depicts a HPLC chromatogram for the Working 100 PPM 140HC
Standard Solution of Example 4.
[0052] Figure 5 depicts typical HPLC chromatogram for the Oxycodone API Sample

Solution of Example 4.
DETAILED DESCRIPTION
[0053] In certain embodiments, the invention is directed to a process for
reducing the
amount of 14-hydroxycodeinone in an oxycodone salt composition (e.g.,
oxycodone
hydrochloride API), and to the resultant oxycodone salt composition having a
14-
hydroxycodeinone level of less than 25 ppm recovered from that process. In
certain
embodiments, the present invention is directed to a process for reducing the
amount of
14-hydroxycodeinone in an oxycodone hydrochloride composition comprising
reacting

CA 02557845 2010-07-23
the oxycodone hydrochloride composition with a catalytically effective amount
of a
transition metal compound and a gas comprising hydrogen, at a temperature and
for a
period of time sufficient to reduce the content of 14-hydroxycodeinone to a
level wherein
the resultant oxycodone hydrochloride composition comprises 14-
hydroxycodeinone in
an amount less than 25 ppm, less than about 15 ppm; less than about 10 ppm, or
less than
about 5 ppm.
[0054] The process of the present invention also may result in the reduction
of other
alpha, beta, unsaturated ketones in oxycodone compositions, in addition to 14-
hydroxycodeinone such as, e.g., codeinone.
[0055] In accordance with certain embodiments of the present invention, an
oxycodone
salt composition (e.g., oxycodone hydrochloride API), and a solvent, are fed
into a
reaction apparatus. The composition is then hydrogenated under adequate
conditions for
a sufficient period; the catalyst is removed from the solvent; and the
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level of less than 25
ppm is
isolated and removed, e.g., by crystallization and filtration.
[0056] Hydrogenation of the 14-hydroxycodeinone in the processes of the
present
invention can be accomplished by using, e.g., pressurized-catalytic
hydrogenation or
catalytic transfer hydrogenation in an appropriate acid, e.g., acetic acid. A
particular
hydrogenation reaction employs hydrogen gas or NaHP02 along with a palladium-
carbon
catalyst. In certain embodiments, a hydrogen donor for use in the
hydrogenation of the
14-hydroxycodeinone can be selected from hydrogen, primary and secondary
alcohols,
primary and secondary amines, carboxylic acids and their esters and amine
salts, readily
dehydrogenatable hydrocarbons (e.g., lower alkyl-substituted aromatic
hydrocarbons
such as ethylbenzene, diethylbenzene, isopropylbenzene, diisopropylbenzene, o-
ethyltoluene, m-ethyltoluene, p-ethyltoluene, o-isopropyltoluene, m-
isopropyltoluene, p-
isopropyltoluene, ethylnaphthalene, propylnapththalene, isopropylnaphthalene,
and
diethylnaphthalene; paraffins such as ethane, propane, n-butane, isobutane, n-
pentane,
isopentane, n-hexane, n-heptane, n-octane, n-nonane, n-decane, and branched
chain
isomers thereof; cycloparaffms such as cyclobutane, cyclopentane, cyclohexane,
11

CA 02557845 2010-07-23
methylcyclopentane, methylcyclohexane, and ethylcyclopentane; olefins such as
ethylene, propylene, 1-butene, 2-butene, 1-pentene, 2-pentene, 1-hexene, 2-
hexene, 3-
hexene, and branched chain derivatives thereof), clean reducing agents (e.g.,
polymer-
supported organotin hydrides, and any suitable combination thereof. In certain

embodiments, the hydrogenation can be performed as disclosed in U.S.
Provisional
Application No. 60/477,968, filed June 12, 2003, entitled "Hydrogenation of
Opioids
Without Hydrogen Gas Feed."
100571 In certain embodiments, the hydrogenation is carried out at a pressure
from about
PSIG to about 200 PSIG, or from about 40 PSIG to about 60 PSIG. In certain
embodiments, the hydrogenation is carried out at a temperature of from about
20 C to
about 100 C, or from about 40 C to about 85 C.
[0058] In certain embodiments, the hydrogenation is carried out at a pH of
less than 5,
less than 3, or less than 1, e.g., about 0.5.
100591 In certain embodiments of the present invention, the 14-
hydroxycodeinone is
converted to oxycodone by hydrogenation utilizing diphenylsilane and
Pd(Ph3P)/ZnC12
and sodium hypophosphite in conjunction with a Pd/C catalyst in aqueous
organic acid;
or Pd/C catalytic transfer hydrogenation.
100601 The total reaction time of the hydrogenation reaction is for a duration
sufficient to
reduce the content of the 14-hydroxycodeinone to a level that is less than 25
ppm, less
than about 15 ppm, less than about 10 ppm, or less than about 5 ppm. The
actual reaction
time can vary depending upon the temperature and efficiency of the
hydrogenation
system. Depending on the hydrogenation conditions (e.g., temperature and
pressure), the
total reaction time to achieve the desired reduction in 14-hydroxycodeinone
can be, e.g.,
from about 10 minutes to about 36 hours. The hydrogenation of the 14-
hydroxycodeinone can be carried out in the presence of a noble metal catalyst.
In certain
embodiments, suitable catalysts can be selected from Raney ' cobalt, Raney
nickel,
palladium on carbon, platinum on carbon, palladium on alumina, platinum oxide,
1 Registered trade-mark of W.R. Grace it Co.-Conn., of Maryland, U.S.A.
12

CA 02557845 2010-07-23
ruthenium on alumina, rhodium on alumina, or rhodium on carbon, among others.
One
particular catalyst for this reduction is 5% palladium on carbon. The quantity
of
palladium on carbon catalyst can be from about 0.05% w/w to about 50% w/w, or
from
about 0.5% w/w to about 5%, in relation to the treated composition.
[0061] The reaction may be carried out in a solvent such as water; an alcohol
(such as,
e.g., isopropanol, methanol or ethanol); tetrahydrofuran; an aromatic
hydrocarbon (such
as benzene); an ether (such as dioxane); an ester of a lower alkanoic acid
(such as methyl
acetate or ethyl acetate); an amide (such as, e.g., dimethylformamide,
diethylformamide,
dimethylacetomide, or other N-alkyl substituted lower fatty acid amides); N-
methylpyrrolidone; formylmorpholine; 0-methoxypropionitrile; a carboxylic acid
(such
as formic, acetic, propionic acid or other lower alkanoic acid) or an
appropriate mixture
of any two or more of the aforementioned solvents. One particular co-solvent
combination is isopropanol/water.
[0062] In certain embodiments, the solvent is typically mixed with the 14-
hydroxycodeinone-containing composition (e.g., an oxycodone composition) prior
to
hydrogenation.
[0063] In certain embodiments, the invention is directed to the conversion of
an
oxycodone free base composition (with an 8,14-dihydroxy-7,8-dihydrocodeinone
component) to oxycodone hydrochloride. During salt formation reactions, the
8,14-
dihydroxy-7,8-dihydrocodeinone component, and in particular the 8a,14-
dihydroxy-7,8-
dihydrocodeinone component thereof, is converted to 14-hydroxycodeinone by
acid-
catalyzed dehydration. Thus, 14-hydroxycodeinone is increased in the final
product. By
virtue of the present invention, this can be reduced by overloading the amount
of
hydrochloric acid in the salt formation to promote the reaction of 8,14-
dihydroxy-7,8-
dihydrocodeinone, and in particular the 8a,14-dihydroxy-7,8-dihydrocodeinone
component thereof, to 14-hydroxycodeinone and providing reducing conditions
sufficient
for the 14-hydroxycodeinone to be readily converted to oxycodone. In such an
embodiment, the amount of hydrochloric acid is an amount of greater than 1
molar
equivalent as compared to the oxycodone free base. In certain embodiments, the
molar
13

CA 02557845 2010-07-23
equivalent amount of hydrochloric acid can be greater than about 1.2 molar
equivalents
or greater than about 1.4 molar equivalents. In certain embodiments, the
amount of
hydrochloric acid can be about 1.5 molar equivalents. The reducing conditions
sufficient
to drive the 14-hydroxycodeinone to oxycodone can be provided, e.g., by a
catalyst with
a hydrogen donor.
100641 Further, during salt formation, the rate of dehydration of 8,14-
dihydroxy-7,8-
dihydrocodeinone to 14-hydroxycodeinone is reduced as the pH of the solution
increases.
Therefore, in certain embodiments, the pH of the solution can be adjusted to a
pH of from
about 1.5 to about 2.5, preferably to about 1.8, (e.g., from a pH of less than
1) with a
suitable basic agent, e.g., sodium hydroxide. This further minimizes the
formation of 14-
hydroxycodeinone from 8,14-dihydroxy-7,8-dihydrocodeinone and in particular
from the
8a,14-dihydroxy-7,8-dihydrocodeinone
component thereof, during crystallization.
Preferably, the pH adjustment is performed after the hydrogenation step and
prior to
removal of catalyst and isolation of the oxycodone having a 14-
hydroxycodeinone level
of less than 25 ppm.
100651 In certain embodiments it may be necessary to perform the process of
the present
invention, or one or more relevant steps in the process of the present
invention, more than
once in order to reduce the amount of 14-hydroxycodeinone to a desired level,
e.g., less
than about 10 ppm, or less than about 5 ppm.
100661 In certain embodiments of the present invention, oxycodone
hydrochloride
compositions can be prepared by certain alternative processes. Such
alternative processes
preferably result in an oxycodone hydrochloride composition having a 14-
hydroxycodeinone level in an amount of less than 25 ppm. One such alternative
process
is directed to a process for preparing an oxycodone hydrochloride composition
having
less than 25 ppm 14-hydroxycodeinone comprising oxidizing a thebaine
composition to
form 14-hydroxycodeinone composition, the oxidizing being performed at a
suitable pH
to minimize or eliminate the production of 8,14-dihydroxy-7,8-dihydrocodeinone
and in
particular the 8a,14-dihydroxy-7,8-dihydrocodeinone component thereof, in the
14-
hydroxycodeinone composition; hydrogenating the 14-hydroxycodeinone
composition to
14

CA 02557845 2010-07-23
form an oxycodone base composition; and converting the oxycodone base
composition to
an oxycodone hydrochloride composition having less than 25 ppm 14-
hydroxycodeinone.
[0067] Another alternative process is directed to a process for preparing 14-
hydroxycodeinone comprising oxidizing a thebaine composition to form a 14-
hydroxycodeinone composition, the oxidizing being performed at a suitable pH
to
minimize or eliminate the production of 8,14-dihydroxy-7,8-dihydrocodeinone
and in
particular of 8a,14-dihydroxy-7,8-dihydrocodeinone, in the 14-hydroxycodeinone

composition.
[0068] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition comprising reacting an oxycodone base composition
with an
acid having a higher pH than hydrochloric acid to form a corresponding acid
addition salt
of oxycodone, and converting the acid addition salt of oxycodone to oxycodone
hydrochloride. In such an embodiment, the acid may be selected from the group
consisting of tartaric acid, oxalic acid, fiimaric acid, phosphoric acid,
sulfuric acid and
mixtures thereof.
[0069] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level in an amount of
less than
25 ppm comprising contacting an oxycodone base composition having an amount of

8,14-dihydroxy-7,8-dihydrocodeinone with a substance that preferentially
removes the
8,14-dihydroxy-7,8-dihydrocodeinone and in particular 8a,14-
dihydroxy-7,8-
dihydrocodeinone, as compared to the oxycodone base; and converting the
oxycodone
base composition to an oxycodone hydrochloride composition having less than 25
ppm
14-hydroxycodeinone. In preferred embodiments the contacting substance can be
a gel.
In further embodiments, the contacting can comprise passing a solution
comprising the
oxycodone base composition through the substance or can comprise forming a
slurry with
the oxycodone base composition and the gel.
[0070] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level in an amount of
less than
25 ppm comprising subjecting an oxycodone base composition having an amount of

CA 02557845 2010-07-23
8,14-dihydroxy-7,8-dihydrocodeinone to chromatographic separation to
preferentially
remove the 8,14-dihydroxy-7,8-dihydrocodeinone and in particular 8a,14-
dihydroxy-7,8-
dihydrocodeinone as compared to the oxycodone base; and converting the
oxycodone
base composition to an oxycodone hydrochloride composition having less than 25
ppm
14-hydroxycodeinone. In preferred embodiments, the chromatographic separation
is a
simulated moving bed.
[0071] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level in an amount of
less than
25 ppm comprising contacting an oxycodone hydrochloride composition having an
amount of 14-hydroxycodeinone with a substance that preferentially removes the
14-
hydroxycodeinone as compared to the oxycodone hydrochloride; and recovering an

oxycodone hydrochloride composition having less than 25 ppm 14-
hydroxycodeinone.
In preferred embodiments the contacting substance can be a gel. In further
embodiments,
the contacting can comprise passing a solution comprising the oxycodone
hydrochloride
composition through the substance or can comprise forming a slurry with the
oxycodone
hydrochloride composition and the gel.
[0072] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level in an amount of
less than
25 ppm comprising subjecting an oxycodone hydrochloride composition having an
amount of 14-hydroxycodeinone to chromatographic separation to preferentially
remove
the 14-hydroxycodeinone as compared to the oxycodone hydrochloride; and
recovering
an oxycodone hydrochloride composition having less than 25 ppm 14-
hydroxycodeinone.
In preferred embodiments, the chromatographic separation is a simulated moving
bed.
[0073] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level in an amount of
less than
25 ppm comprising reacting in a suitable solvent an oxycodone base composition
having
an amount of 8,14-dihydroxy-7,8-dihydrocodeinone, with boronated polystyrene
resin;
and converting the oxycodone base composition to an oxycodone hydrochloride
16


CA 02557845 2010-07-23
composition having less than 25 ppm 14-hydroxycodeinone. Preferably the
reacting is
performed at a temperature below about 20 degrees C.
[0074] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition comprising reacting in a suitable solvent an
oxycodone base
composition with boronated polystyrene resin; and converting the oxycodone
base
composition to an oxycodone hydrochloride composition. Preferably the reacting
is
performed at a temperature below about 20 degrees C.
[0075] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level in an amount of
less than
25 ppm comprising combining hydrochloric acid and an oxycodone base
composition
having an amount of 8,14-dihydroxy-7,8-dihydrocodeinone in a solvent to form a

solution; and spray drying the solution to generate oxycodone hydrochloride
composition
having a 14-hydroxycodeinone level in an amount of less than 25 ppm.
[0076] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition having a 14-hydroxycodeinone level in an amount of
less than
25 ppm comprising combining hydrochloric acid and an oxycodone base
composition
having an amount of 8,14-dihydroxy-7,8-dihydrocodeinone in a solvent to form a

solution; and lyophilizing the solution to generate oxycodone hydrochloride
composition
having a 14-hydroxycodeinone level in an amount of less than 25 ppm.
[0077] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition comprising combining hydrochloric acid and an
oxycodone
base composition in a solvent to form a solution; and spray drying the
solution to
generate oxycodone hydrochloride.
[0078] Another alternative process is directed to a process for preparing an
oxycodone
hydrochloride composition comprising combining hydrochloric acid and an
oxycodone
base composition in a solvent to form a solution; and lyophilizing the
solution to generate
oxycodone hydrochloride.
FURTHER EMBODIMENTS
17

CA 02557845 2010-07-23
100791 The oxycodone hydrochloride having a 14-hydroxycodeinone level of less
than 25
ppm can be incorporated into pharmaceutical dosage forms, e.g., by admixtures
of the
oxycodone hydrochloride having a 14-hydroxycodeinone level of less than 25 ppm
with
conventional excipients, i.e., pharmaceutically acceptable organic or
inorganic carrier
substances. For oral formulations, the dosage forms can provide a sustained
release of
the active. Suitable pharmaceutically acceptable carriers include but are not
limited to,
alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols,
gelate,
carbohydrates such as lactose, amylose or starch, magnesium stearate, talc,
silicic acid,
viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides,
pentaerythritol
fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, etc. The
pharmaceutical
preparations can be sterilized and if desired mixed with auxiliary agents,
e.g., lubricants,
disintegrants, preservatives, stabilizers, wetting agents, emulsifiers, salts
for influencing
osmotic pressure buffers, coloring, flavoring and/or aromatic substances and
the like.
The compositions intended for oral use may be prepared according to any method
known
in the art and such compositions may contain one or more agents selected from
the group
consisting of inert, non-toxic pharmaceutically acceptable excipients which
are suitable
for the manufacture of tablets. Such excipients include, for example an inert
diluent such
as lactose; granulating and disintegrating agents such as cornstarch; binding
agents such
as starch; and lubricating agents such as magnesium stearate. The tablets may
be
uncoated or they may be coated by known techniques for elegance or to delay
release of
the active ingredients. Formulations for oral use may also be presented as
hard gelatin
capsules wherein the active ingredient is mixed with an inert diluent. The
oral dosage
forms of the present invention may be in the form of tablets (sustained
release and/or
immediate release), troches, lozenges, powders or granules, hard or soft
capsules,
microparticles (e.g., microcapsules, microspheres and the like), buccal
tablets,
suppositories, solutions, suspensions, etc.
100801 In certain embodiments, the present invention provides for a method of
treating
pain by administering to a human patient the dosage forms described herein.
10081] When the dosage form is oral, the dosage form of the present invention
contains
from about 10 mg to about 320 mg of oxycodone hydrochloride having a 14-
18

1
CA 02557845 2010-07-23
hydroxycodeinone level of less than 25 ppm. Particularly preferred dosages for
twice
daily dosing are about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30
mg, about
40 mg, about 50 mg, about 60 mg, about 80 mg, about 100 mg, or about 160 mg.
Particularly preferred dosages for once daily dosing are about 10 mg, about 20
mg, about
30 mg, about 40 mg, about 60 mg, about 80 mg, about 100 mg, about 120 mg,
about 160
mg, or about 320 mg. The oxycodone hydrochloride having a 14-hydroxycodeinone
level of less than 25 ppm can also be formulated with suitable
pharmaceutically
acceptable excipients to provide a sustained release of the oxycodone
hydrochloride
having a 14-hydroxycodeinone level of less than 25 ppm. Such formulations can
be
prepared in accordance with U.S. Patent Nos. 5,266,331; 5,508,042; 5,549,912;
and
5,656,295.
[0082] The oxycodone hydrochloride having a 14-hydroxycodeinone level of less
than 25
ppm can be formulated as a sustained release oral formulation in any suitable
tablet,
coated tablet or multiparticulate formulation known to those skilled in the
art. The
sustained release dosage form may include a sustained release material which
is
incorporated into a matrix along with the oxycodone or salt thereof.
[0083] The sustained release dosage form may optionally comprise particles
containing
oxycodone having a 14-hydroxycodeinone level of less than 25 ppm. In certain
embodiments, the particles have a diameter from about 0.1 mm to about 2.5 mm,
preferably from about 0.5 mm to about 2 mm. Preferably, the particles are film
coated
with a material that permits release of the active at a sustained rate in an
aqueous
medium. The film coat is chosen so as to achieve, in combination with the
other stated
properties, desired release properties. The sustained release coating
formulations of the
present invention should preferably be capable of producing a strong,
continuous film
that is smooth and elegant, capable of supporting pigments and other coating
additives,
non¨toxic, inert, and tack¨free.
COATED BEADS
[0084] In certain embodiments of the present invention a hydrophobic material
is used to
coat inert pharmaceutical beads such as nu panel 18/20 beads, and a plurality
of the
19

CA 02557845 2010-07-23
resultant solid sustained release beads may thereafter be placed in a gelatin
capsule in an
amount sufficient to provide an effective sustained release dose when ingested
and
contacted by an environmental fluid, e.g., gastric fluid or dissolution media.
[0085] The sustained release bead formulations of the present invention slowly
release
the active of the present invention, e.g., when ingested and exposed to
gastric fluids, and
then to intestinal fluids. The sustained release profile of the formulations
of the invention
can be altered, for example, by varying the amount of overcoating with the
hydrophobic
material, altering the manner in which a plasticizer is added to the
hydrophobic material,
by varying the amount of plasticizer relative to hydrophobic material, by the
inclusion of
additional ingredients or excipients, by altering the method of manufacture,
etc. The
dissolution profile of the ultimate product may also be modified, for example,
by
increasing or decreasing the thickness of the retardant coating.
[0086] Spheroids or beads coated with the agent(s) of the present are
prepared, e.g., by
dissolving the agent(s) in water and then spraying the solution onto a
substrate, for
example, nu pariel 18/20 beads, using a Wuster insert. Optionally, additional
ingredients
are also added prior to coating the beads in order to assist the binding of
the active to the
beads, and/or to color the solution, etc. For example, a product which
includes
hydroxypropylmethylcellulose, etc. with or without colorant (e.g., Opadrye,
commercially available from Colorcon, Inc.) may be added to the solution and
the
solution mixed (e.g., for about 1 hour) prior to application of the same onto
the beads.
The resultant coated substrate, in this example beads, may then be optionally
overcoated
with a barrier agent, to separate the active(s) from the hydrophobic sustained
release
coating. An example of a suitable barrier agent is one which comprises
hydroxypropylmethylcellulose. However, any film-former known in the art may be
used.
It is preferred that the barrier agent does not affect the dissolution rate of
the final
product.
[0087] The beads may then be overcoated with an aqueous dispersion of the
hydrophobic
material. The aqueous dispersion of hydrophobic material preferably further
includes an
effective amount of plasticizer, e.g. triethyl citrate. Pre-formulated aqueous
dispersions

CA 02557845 2010-07-23
of ethylcellulose, such as Aquacoate or Surelease , may be used. If Surelease
is used, it
is not necessary to separately add a plasticizer. Alternatively, pre-
formulated aqueous
dispersions of acrylic polymers such as Eudragit can be used.
[0088] The coating solutions of the present invention preferably contain, in
addition to
the film¨former, plasticizer, and solvent system (i.e., water), a colorant to
provide
elegance and product distinction. Color may be added to the solution of the
therapeutically active agent instead, or in addition to the aqueous dispersion
of
hydrophobic material. For example, color may be added to Aquacoat via the use
of
alcohol or propylene glycol based color dispersions, milled aluminum lakes and

opacifiers such as titanium dioxide by adding color with shear to water
soluble polymer
solution and then using low shear to the plasticized Aquacoat . Alternatively,
any
suitable method of providing color to the formulations of the present
invention may be
used. Suitable ingredients for providing color to the formulation when an
aqueous
dispersion of an acrylic polymer is used include titanium dioxide and color
pigments,
such as iron oxide pigments. The incorporation of pigments, may, however,
increase the
retard effect of the coating.
[0089] Plasticized hydrophobic material may be applied onto the substrate
comprising
the agent(s) by spraying using any suitable spray equipment known in the art.
In a
preferred method, a Wurster fluidized¨bed system is used in which an air jet,
injected
from underneath, fluidizes the core material and effects drying while the
acrylic polymer
coating is sprayed on. A sufficient amount of the hydrophobic material to
obtain a
predetermined sustained release of the agent(s) when the coated substrate is
exposed to
aqueous solutions, e.g. gastric fluid, may be applied. After coating with the
hydrophobic
material, a further overcoat of a film-former, such as Opadry , is optionally
applied to the
beads. This overcoat is provided, if at all, in order to substantially reduce
agglomeration
of the beads.
[0090] The release of the agent(s) from the sustained release formulation of
the present
invention can be further influenced, i.e., adjusted to a desired rate, by the
addition of one
or more release-modifying agents, or by providing one or more passageways
through the
21

CA 02557845 2010-07-23
coating. The ratio of hydrophobic material to water soluble material is
determined by,
among other factors, the release rate required and the solubility
characteristics of the
materials selected.
[0091] The release-modifying agents which function as pore-formers may be
organic or
inorganic, and include materials that can be dissolved, extracted or leached
from the
coating in an environment of use. The pore-formers may comprise one or more
hydrophilic materials such as hydroxypropylmethylcellulose.
[0092] The sustained release coatings of the present invention can also
include erosion-
promoting agents such as starch and gums.
[0093] The sustained release coatings of the present invention can also
include materials
useful for making microporous lamina in the environment of use, such as
polycarbonates
comprised of linear polyesters of carbonic acid in which carbonate groups
reoccur in the
polymer chain.
100941 The release-modifying agent may also comprise a semi-permeable polymer.
[0095] In certain preferred embodiments, the release-modifying agent is
selected from
hydroxypropylmethylcellulose, lactose, metal stearates, and mixtures of any of
the
foregoing.
[0096] The sustained release coatings of the present invention may also
include an exit
means comprising at least one passageway, orifice, or the like. The passageway
may be
formed by such methods as those disclosed in U.S. Patent Nos. 3,845,770;
3,916,8989;
4,063,064; and 4,088,864.
MATRIX FORMULATIONS
[0097] In other embodiments of the present invention, the sustained release
formulation
is achieved via a matrix optionally having a sustained release coating as set
forth herein.
The materials suitable for inclusion in a sustained release matrix may depend
on the
method used to form the matrix.
22

CA 02557845 2010-07-23
[0098] For example, a matrix in addition to the oxycodone hydrochloride having
a 14-
hydroxycodeinone level of less than 25 ppm may include:
[0099] Hydrophilic and/or hydrophobic materials, such as gums, cellulose
ethers, acrylic
resins, protein derived materials; the list is not meant to be exclusive, and
any
pharmaceutically acceptable hydrophobic material or hydrophilic material which
is
capable of imparting sustained release of the agent(s) and which melts (or
softens to the
extent necessary to be extruded) may be used in accordance with the present
invention.
[0100] Digestible, long chain (C8-050, especially C12-C40), substituted or
unsubstituted
hydrocarbons, such as fatty acids, fatty alcohols, glyceryl esters of fatty
acids, mineral
and vegetable oils and waxes, and stearyl alcohol; and polyalkylene glycols.
[0101] Of these polymers, acrylic polymers, especially Eudragit RSPO - the
cellulose
ethers, especially hydroxyalkylcelluloses and carboxyalkylcelluloses, are
preferred. The
oral dosage form may contain between 1% and 80% (by weight) of at least one
hydrophilic or hydrophobic material.
[0102] When the hydrophobic material is a hydrocarbon, the hydrocarbon
preferably has
a melting point of between 25 and 90 C. Of the long chain hydrocarbon
materials, fatty
(aliphatic) alcohols are preferred. The oral dosage form may contain up to 60%
(by
weight) of at least one digestible, long chain hydrocarbon.
[0103] Preferably, the oral dosage form contains up to 60% (by weight) of at
least one
polyalkylene glycol.
[0104] The hydrophobic material is preferably selected from the group
consisting of
alkylcelluloses, acrylic and methacrylic acid polymers and copolymers,
shellac, zein,
hydrogenated castor oil, hydrogenated vegetable oil, or mixtures thereof. In
certain
preferred embodiments of the present invention, the hydrophobic material is a
pharmaceutically acceptable acrylic polymer, including but not limited to
acrylic acid and
methacrylic acid copolymers, methyl methacrylate, methyl methacrylate
copolymers,
ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate
copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid
alkylamine
23

CA 02557845 2010-07-23
copolymer, poly(methyl methacrylate), poly(methacrylic acid)(anhydride),
polymethacrylate, polyacrylamide, poly(methacrylic acid anhydride), and
glycidyl
methacrylate copolymers. In other embodiments, the hydrophobic material is
selected
from materials such as hydroxyalkylcelluloses such as
hydroxypropylmethylcellulose and
mixtures of the foregoing.
[0105] Preferred hydrophobic materials are water-insoluble with more or less
pronounced hydrophilic and/or hydrophobic trends. Preferably, the hydrophobic
materials
useful in the invention have a melting point from about 25300 to about 200 C,
preferably
from about 45 C to about 90 C. Specifically, the hydrophobic material may
comprise
natural or synthetic waxes, fatty alcohols (such as lauryl, myristyl, stearyl,
cetyl or
preferably cetostearyl alcohol), fatty acids, including but not limited to
fatty acid esters,
fatty acid glycerides (mono-, di-, and tri-glycerides), hydrogenated fats,
hydrocarbons,
normal waxes, stearic aid, stearyl alcohol and hydrophobic and hydrophilic
materials
having hydrocarbon backbones. Suitable waxes include, for example, beeswax,
glycowax, castor wax and carnauba wax. For purposes of the present invention,
a wax-
like substance is defined as any material which is normally solid at room
temperature and
has a melting point of from about 25 to about 100 C.
[0106] Suitable hydrophobic materials which may be used in accordance with the
present
invention include digestible, long chain (C8-050, especially C12-C40),
substituted or
unsubstituted hydrocarbons, such as fatty acids, fatty alcohols, glyceryl
esters of fatty
acids, mineral and vegetable oils and natural and synthetic waxes.
Hydrocarbons having a
melting point of between 25 and 90 C are preferred. Of the long chain
hydrocarbon
materials, fatty (aliphatic) alcohols are preferred in certain embodiments.
The oral dosage
form may contain up to 60% (by weight) of at least one digestible, long chain
hydrocarbon.
[0107] Preferably, a combination of two or more hydrophobic materials are
included in
the matrix formulations. If an additional hydrophobic material is included, it
is preferably
selected from natural and synthetic waxes, fatty acids, fatty alcohols, and
mixtures of the
24

CA 02557845 2010-07-23
same. Examples include beeswax, camauba wax, stearic acid and stearyl alcohol.
This list
is not meant to be exclusive.
10108] One particular suitable matrix comprises at least one water soluble
hydroxyalkyl
cellulose, at least one C12-C36, preferably C14-C22, aliphatic alcohol and,
optionally, at
least one polyalkylene glycol. The at least one hydroxyalkyl cellulose is
preferably a
hydroxy (C1 to C6) alkyl cellulose, such as hydroxypropylcellulose,
hydroxypropylmethylcellulose and, especially, hydroxyethylcellulose. The
amount of the
at least one hydroxyalkyl cellulose in the present oral dosage form will be
determined,
inter alia, by the precise rate of oxycodone hydrochloride release required.
The at least
one aliphatic alcohol may be, for example, lauryl alcohol, myristyl alcohol or
stearyl
alcohol. In particularly preferred embodiments of the present oral dosage
form, however,
the at least one aliphatic alcohol is cetyl alcohol or cetostearyl alcohol.
The amount of the
at least one aliphatic alcohol in the present oral dosage form will be
determined, as
above, by the precise rate of opioidoxycodone release required. It will also
depend on
whether at least one polyalkylene glycol is present in or absent from the oral
dosage
form. In the absence of at least one polyalkylene glycol, the oral dosage form
preferably
contains between 20% and 50% (by wt) of the at least one aliphatic alcohol.
When at
least one polyalkylene glycol is present in the oral dosage form, then the
combined
weight of the at least one aliphatic alcohol and the at least one polyalkylene
glycol
preferably constitutes between 20% and 50% (by wt) of the total dosage.
[0109] In one embodiment, the ratio of, e.g., the at least one hydroxyalkyl
cellulose or
acrylic resin to the at least one aliphatic alcohol/ polyalkylene glycol
determines, to a
(w/w) of the at least one hydroxyalkyl cellulose to the at least one aliphatic

alcohol/polyalkylene glycol of between 1:2 and 1:4 is preferred, with a ratio
of between
1:3 and 1:4 being particularly preferred.
[0110] The at least one polyalkylene glycol may be, for example, polypropylene
glycol
or, which is preferred, polyethylene glycol. The number average molecular
weight of the
at least one polyalkylene glycol is preferred between 1,000 and 15,000
especially
between 1,500 and 12,000.

CA 02557845 2010-07-23
[0111] Another suitable sustained release matrix would comprise an
alkylcellulose
(especially ethyl cellulose), a C12 to C36 aliphatic alcohol and, optionally,
a polyalkylene
glycol.
[0112] In another preferred embodiment, the matrix includes a pharmaceutically

acceptable combination of at least two hydrophobic materials.
[0113] In addition to the above ingredients, a sustained release matrix may
also contain
suitable quantities of other materials, e.g. diluents, lubricants, binders,
granulating aids,
colorants, flavorants and glidants that are conventional in the pharmaceutical
art.
MATRIX ¨ PARTICULATES
[0114] In order to facilitate the preparation of a solid, sustained release,
oral dosage form
according to this invention, any method of preparing a matrix formulation
known to those
skilled in the art may be used. For example incorporation in the matrix may be
effected,
for example, by (a) forming granules comprising at least one water soluble
hydroxyalkyl
cellulose, and the oxycodone hydrochloride having a 14-hydroxycodeinone level
of less
than 25 ppm; (b) mixing the hydroxyalkyl cellulose containing granules with at
least one
C12 - C36 aliphatic alcohol; and (c) optionally, compressing and shaping the
granules.
Preferably, the granules are formed by wet granulating the hydroxalkyl
cellulose granules
with water.
[0115] In yet other alternative embodiments, a spheronizing agent, together
with the
active can be spheronized to form spheroids. Microcrystalline cellulose is a
preferred
spheronizing agent. A suitable microcrystalline cellulose is, for example, the
material
sold as Avicel PH 101 (Trade Mark, FMC Corporation). In such embodiments, in
addition to the active ingredient and spheronizing agent, the spheroids may
also contain a
binder. Suitable binders, such as low viscosity, water soluble polymers, will
be well
known to those skilled in the pharmaceutical art. However, water soluble
hydroxy lower
alkyl cellulose, such as hydroxypropylcellulose, are preferred. Additionally
(or
alternatively) the spheroids may contain a water insoluble polymer, especially
an acrylic
polymer, an acrylic copolymer, such as a methacrylic acid-ethyl acrylate
copolymer, or
26

CA 02557845 2010-07-23
ethyl cellulose. In such embodiments, the sustained release coating will
generally include
a hydrophobic material such as (a) a wax, either alone or in admixture with a
fatty
alcohol; or (b) shellac or zein.
MELT EXTRUSION MATRIX
[0116] Sustained release matrices can also be prepared via melt-granulation or
melt-
extrusion techniques. Generally, melt-granulation techniques involve melting a
normally
solid hydrophobic material, e.g. a wax, and incorporating a powdered drug
therein. To
obtain a sustained release dosage form, it may be necessary to incorporate an
additional
hydrophobic substance, e.g. ethylcellulose or a water-insoluble acrylic
polymer, into the
molten wax hydrophobic material. Examples of sustained release formulations
prepared
via melt-granulation techniques are found in U.S. Patent No. 4,861,598.
[0117] The additional hydrophobic material may comprise one or more water-
insoluble
wax-like thermoplastic substances possibly mixed with one or more wax-like
thermoplastic substances being less hydrophobic than said one or more water-
insoluble
wax-like substances. In order to achieve constant release, the individual wax-
like
substances in the formulation should be substantially non-degradable and
insoluble in
gastrointestinal fluids during the initial release phases. Useful water-
insoluble wax-like
substances may be those with a water-solubility that is lower than about
1:5,000 (w/w).
[0118] In addition to the above ingredients, a sustained release matrix may
also contain
suitable quantities of other materials, e.g., diluents, lubricants, binders,
granulating aids,
colorants, flavorants and glidants that are conventional in the pharmaceutical
art. The
quantities of these additional materials will be sufficient to provide the
desired effect to
the desired formulation.
[0119] In addition to the above ingredients, a sustained release matrix
incorporating melt-
extruded multiparticulates may also contain suitable quantities of other
materials, e.g.
diluents, lubricants, binders, granulating aids, colorants, flavorants and
glidants that are
conventional in the pharmaceutical art in amounts up to about 50% by weight of
the
particulate if desired.
27

õ
CA 02557845 2010-07-23
[0120] Specific examples of pharmaceutically acceptable carriers and
excipients that may
be used to formulate oral dosage forms are described in the Handbook of
Pharmaceutical
Excipients, American Pharmaceutical Association (1986).
MELT EXTRUSION MULTIPARTICULATES
[0121] The preparation of a suitable melt-extruded matrix according to the
present
invention may, for example, include the steps of blending the oxycodone
hydrochloride
having a 14-hydroxycodeinone level of less than 25 ppm together with at least
one
hydrophobic material and preferably the additional hydrophobic material to
obtain a
homogeneous mixture. The homogeneous mixture is then heated to a temperature
sufficient to at least soften the mixture sufficiently to extrude the same.
The resulting
homogeneous mixture is then extruded to form strands. The extrudate is
preferably
cooled and cut into multiparticulates by any means known in the art. The
strands are
cooled and cut into multiparticulates. The multiparticulates are then divided
into unit
doses. The extrudate preferably has a diameter of from about 0.1 to about 5 mm
and
provides sustained release of the therapeutically active agent for a time
period of from
about 8 to about 24 hours.
[0122] An optional process for preparing the melt extrusions of the present
invention
includes directly metering into an extruder a hydrophobic material, the
oxycodone
hydrochloride having a 14-hydroxycodeinone level of less than 25 ppm, and an
optional
binder; heating the homogenous mixture; extruding the homogenous mixture to
thereby
form strands; cooling the strands containing the homogeneous mixture; cutting
the
strands into particles having a size from about 0.1 mm to about 12 mm; and
dividing said
particles into unit doses. In this aspect of the invention, a relatively
continuous
manufacturing procedure is realized.
[0123] The diameter of the extruder aperture or exit port can also be adjusted
to vary the
thickness of the extruded strands. Furthermore, the exit part of the extruder
need not be
round; it can be oblong, rectangular, etc. The exiting strands can be reduced
to particles
using a hot wire cutter, guillotine, etc.
28

CA 02557845 2010-07-23
[0124] The melt extruded multiparticulate system can be, for example, in the
form of
granules, spheroids or pellets depending upon the extruder exit orifice. For
purposes of
the present invention, the terms "melt-extruded multiparticulate(s)" and "melt-
extruded
multiparticulate system(s)" and "melt-extruded particles" shall refer to a
plurality of units,
preferably within a range of similar size and/or shape and containing one or
more active
agents and one or more excipients, preferably including a hydrophobic material
as
described herein. In this regard, the melt-extruded multiparticulates will be
of a range of
from about 0.1 to about 12 mm in length and have a diameter of from about 0.1
to about
mm. In addition, it is to be understood that the melt-extruded
multiparticulates can be
any geometrical shape within this size range. Alternatively, the extrudate may
simply be
cut into desired lengths and divided into unit doses of the therapeutically
active agent
without the need of a spheronization step.
[0125] In one preferred embodiment, oral dosage forms are prepared to include
an
effective amount of melt-extruded multiparticulates within a capsule. For
example, a
plurality of the melt-extruded multiparticulates may be placed in a gelatin
capsule in an
amount sufficient to provide an effective sustained release dose when ingested
and
contacted by gastric fluid.
[0126] In another preferred embodiment, a suitable amount of the
multiparticulate
extrudate is compressed into an oral tablet using conventional tableting
equipment using
standard techniques. Techniques and compositions for making tablets
(compressed and
molded), capsules (hard and soft gelatin) and pills are also described in
Remington's
Pharmaceutical Sciences, (Arthur Osol, editor), 1553-1593 (1980).
[0127] In yet another preferred embodiment, the extrudate can be shaped into
tablets as
set forth in U.S. Patent No. 4,957,681 (Klimesch, et. al.), described in
additional detail
above.
[0128] Optionally, the sustained release melt-extruded multiparticulate
systems or tablets
can be coated, or the gelatin capsule containing the multiparticulates can be
further
coated, with a sustained release coating such as the sustained release
coatings described
above. Such coatings preferably include a sufficient amount of hydrophobic
material to
29

CA 02557845 2010-07-23
obtain a weight gain level from about 2 to about 30 percent, although the
overcoat may
be greater depending upon the desired release rate, among other things.
[0129] The melt-extruded unit dosage forms of the present invention may
further include
combinations of melt-extruded particles before being encapsulated.
Furthermore, the unit
dosage forms can also include an amount of an immediate release agent for
prompt
release. The immediate release agent may be incorporated, e.g., as separate
pellets within
a gelatin capsule, or may be coated on the surface of the multiparticulates
after
preparation of the dosage forms (e.g., sustained release coating or matrix-
based). The unit
dosage forms of the present invention may also contain a combination of
sustained
release beads and matrix multiparticulates to achieve a desired effect.
[0130] The sustained release formulations of the present invention preferably
slowly
release the agent(s), e.g., when ingested and exposed to gastric fluids, and
then to
intestinal fluids. The sustained release profile of the melt-extruded
formulations of the
invention can be altered, for example, by varying the amount of retardant,
i.e., hydropho-
bic material, by varying the amount of plasticizer relative to hydrophobic
material, by the
inclusion of additional ingredients or excipients, by altering the method of
manufacture,
etc.
[0131] In other embodiments of the invention, the melt extruded material is
prepared
without the inclusion of the oxycodone hydrochloride having a 14-
hydroxycodeinone
level of less than 25 ppm, which can be added thereafter to the extrudate.
Such
formulations typically will have the agents blended together with the extruded
matrix
material, and then the mixture would be tableted in order to provide a slow
release
formulation.
COATINGS
[0132] The dosage forms of the present invention may optionally be coated with
one or
more materials suitable for the regulation of release or for the protection of
the
formulation. In one embodiment, coatings are provided to permit either pH-
dependent or
pH-independent release. A pH-dependent coating serves to release the active in
desired

VI
CA 02557845 2010-07-23
areas of the gastro-intestinal (GI) tract, e.g., the stomach or small
intestine, such that an
absorption profile is provided which is capable of providing at least about
eight hours and
preferably about twelve hours to up to about twenty-four hours of analgesia to
a patient.
When a pH-independent coating is desired, the coating is designed to achieve
optimal
release regardless of pH-changes in the environmental fluid, e.g., the GI
tract. It is also
possible to formulate compositions which release a portion of the dose in one
desired area
of the GI tract, e.g., the stomach, and release the remainder of the dose in
another area of
the GI tract, e.g., the small intestine.
[0133] Formulations according to the invention that utilize pH-dependent
coatings to
obtain formulations may also impart a repeat-action effect whereby unprotected
drug is
coated over the enteric coat and is released in the stomach, while the
remainder, being
protected by the enteric coating, is released further down the
gastrointestinal tract.
Coatings which are pH-dependent may be used in accordance with the present
invention
include shellac, cellulose acetate phthalate (CAP), polyvinyl acetate
phthalate (PVAP),
hydroxypropylmethylcellulose phthalate, and methacrylic acid ester copolymers,
zein,
and the like.
[0134] In certain preferred embodiments, the substrate (e.g., tablet core
bead, matrix
particle) containing the oxycodone hydrochloride having a 14-hydroxycodeinone
level of
less than 25 ppm thereof is coated with a hydrophobic material selected from
(i) an
alkylcellulose; (ii) an acrylic polymer; or (iii) mixtures thereof. The
coating may be
applied in the form of an organic or aqueous solution or dispersion. The
coating may be
applied to obtain a weight gain from about 2 to about 25% of the substrate in
order to
obtain a desired sustained release profile. Coatings derived from aqueous
dispersions are
described, e.g., in detail in U.S. Patent Nos. 5,273,760 and 5,286,493.
[0135] Other examples of sustained release formulations and coatings which may
be used
in accordance with the present invention include those described in U.S.
Patent Nos.
5,324,351; 5,356,467, and 5,472,712.
ALKYLCELLULOSE POLYMERS
31

CA 02557845 2010-07-23
[0136] Cellulosic materials and polymers, including alkylcelluloses, provide
hydrophobic
materials well suited for coating the beads according to the invention. Simply
by way of
example, one preferred alkylcellulosic polymer is ethylcellulose, although the
artisan will
appreciate that other cellulose and/or alkylcellulose polymers may be readily
employed,
singly or in any combination, as all or part of a hydrophobic coating
according to the
invention.
ACRYLIC POLYMERS
[0137] In other preferred embodiments of the present invention, the
hydrophobic material
comprising the sustained release coating is a pharmaceutically acceptable
acrylic
polymer, including but not limited to acrylic acid and methacrylic acid
copolymers,
methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl
methacrylate,
poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylarnide
copolymer,
poly(methyl methacrylate), polymethacrylate, poly(methyl methacrylate)
copolymer,
polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid
anhydride),
and glycidyl methacrylate copolymers.
[0138] In certain preferred embodiments, the acrylic polymer is comprised of
one or
more ammonio methacrylate copolymers. Ammonio methacrylate copolymers are well

known in the art, and are described in NF XVII as fully polymerized copolymers
of
acrylic and methacrylic acid esters with a low content of quaternary ammonium
groups.
[0139] In order to obtain a desirable dissolution profile, it may be necessary
to
incorporate two or more ammonio methacrylate copolymers having differing
physical
properties, such as different molar ratios of the quaternary ammonium groups
to the
neutral (meth)acrylic esters.
[0140] Certain methacrylic acid ester-type polymers are useful for preparing
pH-
dependent coatings which may be used in accordance with the present invention.
For
example, there are a family of copolymers synthesized from diethylaminoethyl
methacrylate and other neutral methacrylic esters, also known as methacrylic
acid
copolymer or polymeric methacrylates, commercially available as Eudragit from
Rohm
32

CA 02557845 2010-07-23
Tech, Inc. There are several different types of Eudragit . For example,
Eudragit E is an
example of a methacrylic acid copolymer which swells and dissolves in acidic
media.
Eudragit L is a methacrylic acid copolymer which does not swell at about pH <
5.7 and
is soluble at about pH > 6. Eudragit S does not swell at about pH < 6.5 and
is soluble at
about pH > 7. Eudragit RL and Eudragit RS are water swellable, and the
amount of
water absorbed by these polymers is pH-dependent, however, dosage forms coated
with
Eudragit RL and RS are pH-independent.
101411 In certain preferred embodiments, the acrylic coating comprises a
mixture of two
acrylic resin lacquers commercially available from Rohm Pharma under the
Tradenames
Eudragit RL3OD and Eudragit RS30D, respectively. Eudragit RL3OD and
Eudragit
RS3OD are copolymers of acrylic and methacrylic esters with a low content of
quaternary
ammonium groups, the molar ratio of ammonium groups to the remaining neutral
(meth)acrylic esters being 1:20 in Eudragit RL3OD and 1:40 in Eudragit
RS30D. The
mean molecular weight is about 150,000. The code designations RL (high
permeability)
and RS (low permeability) refer to the permeability properties of these
agents. Eudragit
RL/RS mixtures are insoluble in water and in digestive fluids. However,
coatings formed
from the same are swellable and permeable in aqueous solutions and digestive
fluids.
10142] The Eudragit RL/RS dispersions of the present invention may be mixed
together
in any desired ratio in order to ultimately obtain a sustained release
formulation having a
desirable dissolution profile. Desirable sustained release formulations may be
obtained,
for instance, from a retardant coating derived from 100% Eudragit RL, 50%
Eudragit
RL and 50% Eudragit RS, and 10% Eudragit RL:Eudragit 90% RS. Of course, one

skilled in the art will recognize that other acrylic polymers may also be
used, such as, for
example, Eudragit L.
PLASTICIZERS
[0143] In embodiments of the present invention where the coating comprises an
aqueous
dispersion of a hydrophobic material, the inclusion of an effective amount of
a plasticizer
in the aqueous dispersion of hydrophobic material will further improve the
physical
properties of the sustained release coating. For example, because
ethylcellulose has a
33

CA 02557845 2010-07-23
relatively high glass transition temperature and does not form flexible films
under normal
coating conditions, it is preferable to incorporate a plasticizer into an
ethylcellulose
coating containing sustained release coating before using the same as a
coating material.
Generally, the amount of plasticizer included in a coating solution is based
on the
concentration of the film-former, e.g., most often from about 1 to about 50
percent by
weight of the film-former. Concentration of the plasticizer, however, can only
be
properly determined after careful experimentation with the particular coating
solution and
method of application.
[0144] Examples of suitable plasticizers for ethylcellulose include water
insoluble
plasticizers such as dibutyl sebacate, diethyl phthalate, triethyl citrate,
tributyl citrate, and
triacetin, although it is possible that other water-insoluble plasticizers
(such as acetylated
monoglycerides, phthalate esters, castor oil, etc.) may be used. Triethyl
citrate is an
especially preferred plasticizer for the aqueous dispersions of ethyl
cellulose of the
present invention.
[0145] Examples of suitable plasticizers for the acrylic polymers of the
present invention
include, but are not limited to citric acid esters such as triethyl citrate NF
XVI, tributyl
citrate, dibutyl phthalate, and possibly 1,2¨propylene glycol. Other
plasticizers which
have proved to be suitable for enhancing the elasticity of the films formed
from acrylic
films such as Eudragit RL/RS lacquer solutions include polyethylene glycols,
propylene
glycol, diethyl phthalate, castor oil, and triacetin. Triethyl citrate is an
especially
preferred plasticizer for the aqueous dispersions of ethyl cellulose of the
present
invention.
[0146] It has further been found that the addition of a small amount of talc
reduces the
tendency of the aqueous dispersion to stick during processing, and acts as a
polishing
agent.
SUSTAINED RELEASE OSMOTIC DOSAGE FORM
101471 Sustained release dosage forms according to the present invention may
also be
prepared as osmotic dosage formulations. The osmotic dosage forms preferably
include a
34

CA 02557845 2010-07-23
bilayer core comprising a drug layer (containing the oxycodone hydrochloride
having a
14-hydroxycodeinone level of less than 25 ppm) and a delivery or push layer,
wherein the
bilayer core is surrounded by a semipermeable wall and optionally having at
least one
passageway disposed therein.
101481 The expression "passageway" as used for the purpose of this invention,
includes
aperture, orifice, bore, pore, porous element through which oxycodone
hydrochloride
having a 14-hydroxycodeinone level of less than 25 ppm can be pumped, diffuse
or
migrate through a fiber, capillary tube, porous overlay, porous insert,
microporous
member, or porous composition. The passageway can also include a compound that

erodes or is leached from the wall in the fluid environment of use to produce
at least one
passageway. Representative compounds for forming a passageway include erodible

poly(glycolic) acid, or poly(lactic) acid in the wall; a gelatinous filament;
a water-
removable poly(vinyl alcohol); leachable compounds such as fluid-removable
pore-
forming polysaccharides, acids, salts or oxides. A passageway can be formed by
leaching
a compound from the wall, such as sorbitol, sucrose, lactose, maltose, or
fructose, to form
a sustained-release dimensional pore-passageway. The dosage form can be
manufactured
with one or more passageways in spaced-apart relation on one or more surfaces
of the
dosage form. A passageway and equipment for forming a passageway are disclosed
in
U.S. Patent Nos. 3,845,770; 3,916,899; 4,063,064 and 4,088,864. Passageways
comprising sustained-release dimensions sized, shaped and adapted as a
releasing-pore
formed by aqueous leaching to provide a releasing-pore of a sustained-release
rate are
disclosed in U.S. Patent Nos. 4,200,098 and 4,285,987.
101491 In certain embodiments the drug layer may also comprise at least one
polymer
hydrogel. The polymer hydrogel may have an average molecular weight of between

about 500 and about 6,000,000. Examples of polymer hydrogels include but are
not
limited to a maltodextrin polymer comprising the formula (C6 H12 05)0420,
wherein n is
3 to 7,500, and the maltodextrin polymer comprises a 500 to 1,250,000 number-
average
molecular weight; a poly(alkylene oxide) represented by, e.g., a poly(ethylene
oxide) and
a poly(propylene oxide) having a 50,000 to 750,000 weight-average molecular
weight,
and more specifically represented by a poly(ethylene oxide) of at least one of
100,000,

CA 02557845 2010-07-23
200,000, 300,000 or 400,000 weight-average molecular weights; an alkali
carboxyalkylcellulose, wherein the alkali is sodium or potassium, the alkyl is
methyl,
ethyl, propyl, or butyl of 10,000 to 175,000 weight-average molecular weight;
and a
copolymer of ethylene-acrylic acid, including methacrylic and ethacrylic acid
of 10,000
to 500,000 number-average molecular weight.
101501 In certain embodiments of the present invention, the delivery or push
layer
comprises an osmopolymer. Examples of an osmopolymer include but are not
limited to a
member selected from the group consisting of a polyalkylene oxide and a
carboxyalkylcellulose. The polyalkylene oxide possesses a 1,000,000 to
10,000,000
weight-average molecular weight. The polyalkylene oxide may be a member
selected
from the group consisting of polymethylene oxide, polyethylene oxide,
polypropylene
oxide, polyethylene oxide having a 1,000,000 average molecular weight,
polyethylene
oxide comprising a 5,000,000 average molecular weight, polyethylene oxide
comprising
a 7,000,000 average molecular weight, cross-linked polymethylene oxide
possessing a
1,000,000 average molecular weight, and polypropylene oxide of 1,200,000
average
molecular weight. Typical osmopolymer carboxyalkylcellulose comprises a member

selected from the group consisting of alkali carboxyalkylcellulose, sodium
carboxymethylcellulose, potassium carboxymethylcellulose, sodium
carboxyethylcellulose, lithium carboxymethylcellulose, sodium
carboxyethylcellulose,
carboxyallcylhydroxyalkylcellulose, carboxymethylhydroxyethyl
cellulose,
carboxyethylhydroxyethylcellulose and carboxymethylhydroxypropylcellulose. The

osmopolymers used for the displacement layer exhibit an osmotic pressure
gradient
across the semipermeable wall. The osmopolymers imbibe fluid into dosage form,

thereby swelling and expanding as an osmotic hydrogel (also known as osmogel),

whereby they push the oxycodone hydrochloride having a 14-hydroxycodeinone
level of
less than 25 ppm thereof from the osmotic dosage form.
[0151] The push layer may also include one or more osmotically effective
compounds
also known as osmagents and as osmotically effective solutes. They imbibe an
environmental fluid, for example, from the gastrointestinal tract, into dosage
form and
contribute to the delivery kinetics of the displacement layer. Examples of
osmotically
36

CA 02557845 2010-07-23
active compounds comprise a member selected from the group consisting of
osmotic salts
and osmotic carbohydrates. Examples of specific osmagents include but are not
limited to
sodium chloride, potassium chloride, magnesium sulfate, lithium phosphate,
lithium
chloride, sodium phosphate, potassium sulfate, sodium sulfate, potassium
phosphate,
glucose, fructose and maltose.
[0152] The push layer may optionally include a hydroxypropylalkylcellulose
possessing
a 9,000 to 450,000 number-average molecular weight. The
hydroxypropylalkylcellulose
is represented by a member selected from the group consisting of
hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropyl
isopropyl
cellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.
[0153] The push layer optionally may comprise a nontoxic colorant or dye.
Examples of
colorants or dyes include but are not limited to Food and Drug Administration
Colorant
(FD&C), such as FD&C No. 1 blue dye, FD&C No. 4 red dye, red ferric oxide,
yellow
ferric oxide, titanium dioxide, carbon black, and indigo.
[0154] The push layer may also optionally comprise an antioxidant to inhibit
the
oxidation of ingredients. Some examples of antioxidants include but are not
limited to a
member selected from the group consisting of ascorbic acid, ascorbyl
palmitate, butylated
hydroxyanisole, a mixture of 2 and 3 tertiary-butyl-4-hydroxyanisole,
butylated
hydroxytoluene, sodium isoascorbate, dihydroguaretic acid, potassium sorbate,
sodium
bisulfate, sodium metabisulfate, sorbic acid, potassium ascorbate, vitamin E,
4-chloro-
2,6-ditertiary butylphenol, alphatocopherol, and propylgallate.
[0155] In certain alternative embodiments, the dosage form comprises a
homogenous
core comprising oxycodone hydrochloride having a 14-hydroxycodeinone level of
less
than 25 ppm, a pharmaceutically acceptable polymer (e.g., polyethylene oxide),

optionally a disintegrant (e.g., polyvinylpyrrolidone), optionally an
absorption enhancer
(e.g., a fatty acid, a surfactant, a chelating agent, a bile salt, etc.). The
homogenous core
is surrounded by a semipermeable wall having a passageway (as defmed above)
for the
release of the oxycodone hydrochloride having a 14-hydroxycodeinone level of
less than
25 ppm.
37

CA 02557845 2010-07-23
[0156] In certain embodiments, the semipermeable wall comprises a member
selected
from the group consisting of a cellulose ester polymer, a cellulose ether
polymer and a
cellulose ester-ether polymer. Representative wall polymers comprise a member
selected
from the group consisting of cellulose acylate, cellulose diacylate, cellulose
triacylate,
cellulose acetate, cellulose diacetate, cellulose triacetate, mono-, di- and
tricellulose
alkenylates, and mono-, di- and tricellulose alkinylates. The poly(cellulose)
used for the
present invention comprises a number-average molecular weight of 20,000 to
7,500,000.
[0157] Additional semipermeable polymers for the purpose of this invention
comprise
acetaldehyde dimethycellulose acetate, cellulose acetate ethylcarbamate,
cellulose acetate
methylcarbamate, cellulose diacetate, propylcarbamate, cellulose acetate
diethylaminoacetate; semipermeable polyamide; semipermeable polyurethane;
semipermeable sulfonated polystyrene; semipermeable cross-linked polymer
formed by
the coprecipitation of a polyanion and a polycation as disclosed in U.S.
Patent Nos.
3,173,876; 3,276,586; 3,541,005; 3,541,006 and 3,546,876; semipermeable
polymers as
disclosed by Loeb and Souriraj an in U.S. Patent No. 3,133,132; semipermeable
crosslinked polystyrenes; semipermeable cross-linked poly(sodium styrene
sulfonate);
semipermeable crosslinked poly(vinylbenzyltrimethyl ammonium chloride); and
semipermeable polymers possessing a fluid permeability of 2.5x10-8 to 2.5x10-2
(cm2
ihratm) expressed per atmosphere of hydrostatic or osmotic pressure difference
across
the semipermeable wall. Other polymers useful in the present invention are
known in the
art in U.S. Patent Nos. 3,845,770; 3,916,899 and 4,160,020; and in Handbook of

Common Polymers, Scott, J. R. and W. J. Roff, 1971, CRC Press, Cleveland,
Ohio.
[0158] In certain embodiments, preferably the semipermeable wall is nontoxic,
inert, and
it maintains its physical and chemical integrity during the dispensing life of
the drug. In
certain embodiments, the dosage form comprises a binder. An example of a
binder
includes, but is not limited to a therapeutically acceptable vinyl polymer
having a 5,000
to 350,000 viscosity-average molecular weight, represented by a member
selected from
the group consisting of poly-n-vinylamide, poly-n-vinylacetamide, poly(vinyl
pynolidone), also known as poly-n-vinylpyrrolidone, poly-n-vinylcaprolactone,
poly-n-
viny1-5-methy1-2-pyrrolidone, and poly-n-vinyl-pyrrolidone copolymers with a
member
38

CA 02557845 2010-07-23
selected from the group consisting of vinyl acetate, vinyl alcohol, vinyl
chloride, vinyl
fluoride, vinyl butyrate, vinyl laureate, and vinyl stearate. Other binders
include for
example, acacia, starch, gelatin, and hydroxypropylalkylcellulose of 9,200 to
250,000
average molecular weight.
[0159] In certain embodiments, the dosage form comprises a lubricant, which
may be
used during the manufacture of the dosage form to prevent sticking to die wall
or punch
faces. Examples of lubricants include but are not limited to magnesium
stearate, sodium
stearate, stearic acid, calcium stearate, magnesium oleate, oleic acid,
potassium oleate,
caprylic acid, sodium stearyl fumarate, and magnesium palmitate.
[0160] In certain preferred embodiments, the present invention includes a
therapeutic
composition comprising an amount of oxycodone hydrochloride having a 14-
hydroxycodeinone level of less than 25 ppm equivalent to 10 to 40 mg oxycodone

hydrochloride, 25 to 500 mg of poly(alkylene oxide) having a 150,000 to
500,000
average molecular weight, 1 to 50 mg of polyvinylpyrrolidone having a 40,000
average
molecular weight, and 0 to about 7.5 mg of a lubricant.
SUPPOSITORIES
[0161] The sustained release formulations of the present invention may be
formulated as
a pharmaceutical suppository for rectal administration comprising a suitable
suppository
base, and oxycodone hydrochloride having a 14-hydroxycodeinone level of less
than 25
ppm. Preparation of sustained release suppository formulations is described
in, e.g., U.S.
Patent No. 5,215,758.
[0162] Prior to absorption, the drug must be in solution. In the case of
suppositories,
solution must be preceded by dissolution of the suppository base, or the
melting of the
base and subsequent partition of the drug from the suppository base into the
rectal fluid.
The absorption of the drug into the body may be altered by the suppository
base. Thus,
the particular suppository base to be used in conjunction with a particular
drug must be
chosen giving consideration to the physical properties of the drug. For
example, lipid-
39

CA 02557845 2010-07-23
soluble drugs will not partition readily into the rectal fluid, but drugs that
are only slightly
soluble in the lipid base will partition readily into the rectal fluid.
[0163] Among the different factors affecting the dissolution time (or release
rate) of the
drugs are the surface area of the drug substance presented to the dissolution
solvent
medium, the pH of the solution, the solubility of the substance in the
specific solvent
medium, and the driving forces of the saturation concentration of dissolved
materials in
the solvent medium. Generally, factors affecting the absorption of drugs from
suppositories administered rectally include suppository vehicle, absorption
site pH, drug
pKa, degree of ionization, and lipid solubility.
[0164] The suppository base chosen should be compatible with the active of the
present
invention. Further, the suppository base is preferably non-toxic and
nonirritating to
mucous membranes, melts or dissolves in rectal fluids, and is stable during
storage.
[0165] In certain preferred embodiments of the present invention for both
water-soluble
and water-insoluble drugs, the suppository base comprises a fatty acid wax
selected from
the group consisting of mono-, di- and triglycerides of saturated, natural
fatty acids of the
chain length C12 to C.
[0166] In preparing the suppositories of the present invention other
excipients may be
used. For example, a wax may be used to form the proper shape for
administration via the
rectal route. This system can also be used without wax, but with the addition
of diluent
filled in a gelatin capsule for both rectal and oral administration.
[0167] Examples of suitable commercially available mono-, di- and
triglycerides include
saturated natural fatty acids of the 12-18 carbon atom chain sold under the
trade name
Novata TM (types AB, AB, B,BC, BD, BBC, E, BCF, C, D and 299), manufactured by

Henkel, and Witepsol TM (types H5, H12, H15, H175, H185, H19, H32, H35, H39,
H42,
W25, W31, W35, W45, S55, S58, E75, E76 and E85), manufactured by Dynamit
Nobel.
[0168] Other pharmaceutically acceptable suppository bases may be substituted
in whole
or in part for the above-mentioned mono-, di- and triglycerides. The amount of
base in
the suppository is determined by the size (i.e. actual weight) of the dosage
form, the

CA 02557845 2010-07-23
amount of base (e.g., alginate) and drug used. Generally, the amount of
suppository base
is from about 20 percent to about 90 percent by weight of the total weight of
the
suppository. Preferably, the amount of suppository base in the suppository is
from about
65 percent to about 80 percent, by weight of the total weight of the
suppository.
ADDITIONAL EMBODIMENTS
[0169] The oxycodone hydrochloride having a 14-hydroxycodeinone level of less
than 25
ppm may be used as a substitute for the oxycodone hydrochloride in any
existing
commercial product such as, e.g., Tylox , Roxilox , Roxicet , Percocet ,
Oxycet ,
Percodane, RoxycodoneC, OxyContin and OxyIRS. Such formulations are listed in

the PDR 58th Edition (2004) and the FDA Orange Book.
[0170] The following examples illustrate various aspects of the present
invention. They
are not to be construed to limit the claims in any manner whatsoever.
EXAMPLE 1
[0171] In Example 1, 37.7 g of oxycodone HC1 (35.4 g dry basis, ca. 500 ppm 14-

hydroxycodeinone) was placed in a 500 mL Parr reaction bottle and combined
with 0.55
g 5% Pd/C catalyst, 50% water wet (Johnson Matthey type 87L), and 182.2 g of
61.9%
isopropanol/water (w/w). The mixture was placed under an inert atmosphere and
heated
with shaking to 45 ¨ 50 C. Upon dissolution of all starting material, the
pressure in the
bottle was vented to the atmosphere and hydrogen pressure was applied (45
PSIG) for 4
hours. At the end of the hydrogenation, the hydrogen was vented off and the
solution
was allowed to cool to room temperature.
[0172] The next day, the mixture was heated to 75 C to dissolve the
crystallized solids
and then suction filtered over a 0.2 gm PTFE membrane into a 1 L jacketed
cylindrical
flask (equipped with a condenser, a nitrogen atmosphere, a mechanical stiffer,
a type K
thermocouple, and a programmable refrigerated recirculator). The Parr bottle
was rinsed
with deionized water (11.7 g), which was added to the 1 L flask through the
filter.
Isopropanol (334.7 g) was added to the flask and the mixture was re-heated
with stirring
to 75 C and held to dissolve any crystallized solids. The solution was cooled
with
41

CA 02557845 2010-07-23
stirring to 0 ¨ 10 C over 8 hours (linear ramp) and held at 0 ¨ 10 C for 20
hours. The
crystallized solid was then collected by suction filtration and washed with
107 g of cold
95:5 isopropanol/water (w/w).
[0173] To remove isopropanol from product, the solvent-wet material was
transferred to
a drying dish and placed in a vacuum desiccator with an open container of
deionized
water. The solid was held in this manner, under vacuum, overnight. The
material was
then dried under vacuum at 60 C.
[0174] Analysis of the dried material using the low 14-hydroxycodeinone method
of
Example 4 below gave a result of 6 ppm of 14-hydroxycodeinone.
[0175] Analysis of the dried material using the method of Example 6 below gave
a result
of < 5 ppm of codeinone and 8 ppm of 14-hydroxycodeinone.
EXAMPLE 2
[0176] In Example 2, 35.0 g of oxycodone HC1 (33.3 g dry basis, ca. 4000 ppm
14-
hydroxycodeinone) was placed in a 500 mL Parr reaction bottle and combined
with 0.49
g 5% Pd/C catalyst, 50% water wet (Johnson Matthey type 87L), and 159.9 g of
62.3%
isopropanol/water. The mixture was placed under an inert atmosphere and then
heated
with shaking to 45 ¨ 50 C. Upon dissolution of the starting material, the
pressure in the
bottle was vented to the atmosphere and hydrogen pressure was applied (45
PSIG). After
5.25 hours of shaking, the hydrogen was vented off, and the solution was
allowed to cool
to room temperature. The mixture was re-heated the next day and hydrogenation
was
continued for 4.75 hours.
[0177] The mixture was heated to 75 C and then suction filtered over a 0.2 pm
PTFE
membrane into a 1 L jacketed cylindrical flask (equipped with a distillation
head, a
nitrogen atmosphere, a mechanical stirrer, a type K thermocouple, and a
programmable
refrigerated recirculator). The Parr bottle was rinsed with deionized water
(11.7 g),
which was added to the 1L flask through the filter.
42

CA 02557845 2010-07-23
[0178] Isopropanol (295.6 g) was added to the flask and the mixture was heated
to
boiling (ca. 81 C). To remove water and increase the yield, isopropanol/water
azeotrope
was distilled from the flask until 305.7g had been collected. Fresh
isopropanol (305.6g)
was added and the distillation head was removed and replaced with a condenser.
[0179] The mixture was cooled with stirring from boiling to 0 ¨ 10 C over 8
hours
(linear ramp) and held at 0 ¨ 10 C for 20 hours. The crystallized solid was
then collected
by suction filtration and washed with 107 g of cold 95:5 isopropanol/water.
The material
was dried as described in Example 1.
[0180] Analysis of the dried material using the low 14-hydroxycodeinone method
of
Example 4 below gave a result of <5 ppm of 14-hydroxycodeinone.
[0181] Analysis of the dried material using the method of Example 6 below gave
a result
of < 5 ppm of codeinone and < 5 ppm of 14-hydroxycodeinone.
EXAMPLE 3
[0182] In Example 3, 27.83 g of oxycodone free-base, water wet (24.57 g dry
basis,
0.0779 mol, ca. 3000 ppm 14-hydroxycodeinone), 39.8 g of deionized water,
81.9g of
isopropanol, 0.49 g 5% Pd/C catalyst, 50% water wet (Johnson Matthey type
87L), and
conc. HC1 (11.3 g, 0.117 mol, 1.50 equivalents based on 37.7% HC1 assay) were
combined in a 500 ml Parr shaker bottle.
[0183] The mixture was placed under an inert atmosphere and heated to 75 C
with
shaking. The pressure in the bottle was relieved, and the system was
pressurized with
hydrogen (45 PSIG). The solution was held under these conditions for 21.7
hours.
Analysis by HPLC showed that the ratio of the area of the 8,14-dihydroxy-7,8-
dihydrocodeinone peak to that of oxycodone was reduced from 0.29% to 0.04%
during
this time.
101841 The hydrogen pressure was vented and the system was placed under an
inert
atmosphere. In order to prevent further dehydration of any residual 8,14-
dihydroxy-7,8-
43

CA 02557845 2010-07-23
dihydrocodeinone, the pH of the solution was adjusted from 0.5 to 1.8 with
20.7 g NaOH
saturated isopropanol (some solid sodium hydroxide was also present).
[0185] The solution was re-heated to 75 C and then pressure filtered through
a 0.2 ttm
PTFE membrane filter housed in heat-traced 47 mm SS filter holder into a 500
ml
jacketed cylindrical reactor (condenser, N2, mechanical stirrer, programmable
refrigerated recirculator). The Parr bottle was rinsed with 8.6 g of deionized
water,
which was added to the flask through the filter.
101861 Isopropanol (222.5 g) was added to the solution in the flask and the
resulting
slurry was heated to approximately 75 C to re-dissolve the solids. After
reaching the
desired temperature, the solution was held for two hours (to simulate typical
processing
times). No 14-hydroxycodeinone was detected in a sample of the crystallization
mixture
after this hold.
[0187] The circulator was set to cool from 80 C to 0 C over 8 hours.
Approximately 24
hours after starting the cooling program, the solids were collected by suction
filtration
and washed three times with 95:5 isopropanol /water (232.8 g total). The
material was
dried as described in Example 1.
[0188] Analysis of the dried material using the low 14-hydroxycodeinone method
of
Example 4 below gave a result of 5 ppm of 14-hydroxycodeinone.
[0189] Analysis of the dried material using the method of Example 6 below gave
a result
of < 5 ppm of codeinone and 10 ppm of 14-hydroxycodeinone.
EXAMPLE 4
[0190] Analysis of sample to determine 14-hydroxycodeinone level.
[0191] The products of Examples 1-3 were analyzed to determine the level of 14-

hydroxycodeinone under 100 parts per million (PPM) level by a HPLC method
using a
Waters Atlantis 5 gm dC18, 3 X 250 mm column maintained at 50 C and isocratic

elution using pH 9.35, 17 mM ammonium carbonate buffer and methanol (60:40).
44

CA 02557845 2010-07-23
Quantitation was achieved by measuring the peak area response with UV
detection at 220
nm using external standard. This method utilized mobile phase with volatile
components
that are compatible with LC/MS analysis.
101921 The reagents used were as follows:
1. Ammonium carbonate, analytical reagent grade (Aldrich);
2. Water, HPLC grade;
3. Methanol, HPLC grade;
4. Acetic acid, reagent grade (J. T Baker Glacial Acetic Acid);
5. Ammonium hydroxide, reagent grade;
6. Phosphoric acid, about 85%, A.C.S. reagent;
7. 14-Hydroxycodeinone reference material from Albany Molecular Research,
Inc.
[0193] The equipment used was as follows:
A. HPLC System
1. HPLC system capable of delivering 0.4 mL/minute of mobile phase (Waters
Alliance);
2. UV/Visible detector set to monitor the eluant at 220 rim (Waters 2487
UV/Vis);
3. Autosampler capable of injecting 6 p,L;
4. Integrator or suitable data recording system (Waters Millennium 32
chromatograph system.);
5. Waters, Atlantis dC18 column, 3 x 250 mm, 5 gm;
6. Column heater capable of maintaining a constant temperature of 50 C;
7. On-line vacuum degasser.
B. Equipment for Mobile Phase Preparation
1. pH meter, preferably with automatic temperature compensation (ATC);
2. Ultrasonic bath, Model 5200, Branson;

CA 02557845 2010-07-23
3. 0.45-pm membrane filters for aqueous solvent, WhatmanTM2 or Millipore,
Cellulose acetate or Nylon.
Solutions
101941 17 mM Ammonium carbonate, pH 9.35
1.6 0.1 g of ammonium carbonate was weighed and placed into a 1-L beaker.
1000
mL of water was added to the beaker and stirred with a magnetic stirrer until
the
ammonium carbonate was dissolved. The pH was adjusted to 9.35 - 9.40 with
ammonium hydroxide.
B. Mobile Phase
400 mL of HPLC-grade methanol was mixed with 600 mL of 17mM ammonium
carbonate, pH 9.35-9.40 prepared above. The mixture was filtered through
solvent
membrane filters and then degassed using an on-line vacuum degasser in the
HPLC
system.
C. 0.85% Phosphoric acid solution
10.0 mL of 85% H3PO4 was pipetted into a 1 liter volumetric flask and diluted
to
volume with water and mixed thoroughly.
D. 14-Hydroxycodeinone Working Reference Standard Solutions
A stock 14-hydroxycodeinone standard solution was prepared by weighing 25 2
mg of 14-hydroxycodeinone reference material and transferring it into a 250-mL

volumetric flask. Approximately 100 mL of 0.85 % H3PO4 solution was added to
the
flask and sonicated for approximately 2 minutes or until dissolved. The
solution was
diluted to volume with 0.85 % H3PO4 solution and mixed thoroughly. This was
the
stock 14-hydroxycodeinone standard solution.
2 Trademark of Whatman Paper Company Limited of the United Kingdom for PHASE
SEPARATING PAPER,
CHROMATOGRAPHY PAPER, POLYETHYLENE-BACKED ABSORBENT PAPER, AND FILTER PAPER
46

CA 02557845 2010-07-23
A working solution of 100 ppm 14-hydroxycodeinone standard solution for
system suitability was prepared by pipetting 5.0 mL of the stock 14-
hydroxycodeinone
standard solution into a 100-mL volumetric flask, diluting the solution to
volume with
water and mixing thoroughly.
A working solution of 10 ppm 14-hydroxycodeinone standard solution for
sensitivity was prepared by pipetting 5.0 mL of working 100 ppm 14-
hydroxycodeinone standard solution into a 50-mL volumetric flask, diluting the

solution to volume with water and mixing thoroughly.
A stock hydrocodone standard solution was prepared by weighing 25 2 mg of
hydrocodone reference material and transferring contents into a 250-mL
volumetric
flask. Approximately 100 mL of 0.85 % H3PO4 solution was added to the flask
and
sonicated for approximately 2 minutes or until dissolved. The solution was
diluted to
volume with 0.85 % H3PO4 solution and mixed thoroughly.
E. Hydrocodone Working Reference Standard Solution
Stock Hydrocodone Standard Solution was prepared by weighing 25 2 mg of
Hydrocodone reference material and transferring contents into a 250-mL
volumetric
flask. Approximately 100 mL of 0.85 % H3PO4 solution was added to the flask
and
sonicated for approximately 2 minute or until dissolved. The solution was
diluted to
volume with 0.85 % H3PO4 Solution and mixed thoroughly.
F. Sample solutions
A sample solution was prepared by weighing about 250 mg oxycodone API
sample into a scintillation vial. 5.0 mL of water was pipetted into the vial
to dissolve
the sample. The vial was tightly capped and sonicated for approximately 5
minutes or
until the sample was dissolved. The contents were then shaken and mixed
thoroughly.
G. Resolution Test Mixture (RTM) solution
A solution containing two components, 14-hydroxycodeinone and hydrocodone,
was prepared from the respective stock standard solutions.
47

CA 02557845 2010-07-23
The Resolution Test Mixture (RTM) was prepared by pipetting separately 10.0
mL of each stock standard solution of hydrocodone above and 14-
hydroxycodeinone
above into the same 100 mL volumetric flask and diluted to volume with a
sufficient
amount of water and mixed thoroughly.
H. HPLC Conditions
The HPLC conditions were as follows:
Column: Waters, Atlantis dC18, 3 x 250 mm, 5 pm.
Column temperature: 50 C
Detector wavelength: 220 nm
Injection volume: 6 1
Quantitation: Peak area of 14-hydroxycodeinone
Mobile Phase: (60:40) 17mM ammonium carbonate, pH 9.35 ¨ 9.40:
Methanol
Flow rate: 0.4 mL/minute
Run time: 70 minutes for the samples and 40 minutes for the
standard
and RTM solutions
I. Resolution Test Mixture (RTM) Test
Before performing the system suitability test, a new column was equilibrated
over
night (at least 12 hours) by pumping mobile phase through it at 0.4 mL/min.
After the
new column was equilibrated, 6 ILL of RTM solution was injected into the
equilibrated
system to ensure that the two eluted component peaks did not interfere with
one
another. A typical separation of the system suitability testing solution is
shown in
Figure 3.
J. System Suitability Test
A system suitability test was performed by injecting the Working 100 ppm 14-
hydroxycodeinone standard solution into the system and by performing the
system
suitability test as described in the USP <621> by making six different runs of
6 p,L
injections. The system suitability test results met the following criteria
listed in Table 1
below.
TABLE 1
48

CA 02557845 2010-07-23
Test No. System Suitability Test Specification
1 RSD of peak areas for 14- RSD < 3.0%
hydroxycodeinone (1)
2 RSD of retention time for RSD < 2.0%
14-hydroxycodeinone (1)
3 Column Efficiency N? 2000
(Theoretical Plates of 14-
hydroxycodeinone) (1)
4 Resolution between 14- R? 1.5
hydroxycodeinone and
Hydrocodone (2)
Signal to noise ratio (3) S/N > 10
Note: (1) the working 100 ppm 14-hydroxycodeinone standard solution for
Test
Nos. 1 to 3 was used.
(2) the RTM for Test No. 4 was used.
(3) the working 10 ppm 14-hydroxycodeinone standard solution for Test
No. 5 was used.
[0195] Before starting the experiment, 6 IAL of water was injected to ensure
that there
were no interfering peaks co-eluting with the peak for 14-hydroxycodeinone.
The
following procedure was then conducted.
[0196] The working 100 ppm 14-hydroxycodeinone standard solution was injected
six
times in different runs, and the system was checked to verify that it met the
system
suitability test specifications as listed for Test Nos. 1, 2 and 3 in Table 1
above.
101971 The RTM solution was injected and run once in the HPLC system to
confirm that
the system met the system suitability test specification as listed for Test
No. 4 in Table 1
above.
[0198] The working 10 ppm 14-hydroxycodeinone standard solution was injected
and
run once in the HPLC system to confirm that the system had signal-to-noise
ratio S/N
greater than or equal to 10, as listed in the specification for Test No. 5 in
Table 1 above.
[01991 After the system passed all of the above tests, the following HPLC
procedure was
performed.
49

CA 02557845 2010-07-23
[0200] The working 100 ppm 14-hydroxycodeinone standard solution and the
working
ppm 14-hydroxycodeinone standard solution were each injected separately. Both
working standard solutions were used to quantitate the samples. The setting
and
integration parameters are listed in Table 2 below.
TABLE 2
Integration Setting Parameters
Minimum area 0
Minimum height 0
Threshold 2
Peak width 90.00
Inhibit integration: 0.01 to 20 minutes Eliminates solvent front
[0201] Typical HPLC chromatograms for the working 100 ppm 14-hydroxycodeinone
standard solution and the oxycodone API sample solution are shown in Figure 4
and
Figure 5 respectively. Retention times of the 14-hydroxycodeinone and other
related
substances are presented in Table 3 below.
TABLE 3
Peak ID Relative Retention Time vs. Oxycodone
(RRT)
Oxycodone-N-Oxide (ONO) 0.16
Noroxycodone 0.31
Oxymorphone 0.45
7,8-Dihydro-8, 14-Dihydroxycodeinone 0.58
(DDC)
14-Hydroxycodeine 0.73
14-Hydroxycodeinone 0.79
6-a-Oxycodol 0.96
Hydrocodone 0.95
Oxycodone 1.0
Thebaine 1.89
The following calculations were performed using the results obtained above.
Using Millennium , software, the parameters were entered as follows:

CA 02557845 2010-07-23
In the sample set, the standard concentrations for both working standards (10
and 100
ppm) were calculated as follows:
100 PPM std .conc .¨Wstd corrected for purity
x 0.05
250
W std corrected for purity
PPM std .conc x0.005
250
where Wstd is the weight of standard.
The following were also entered:
Sample weight = weight of sample in mg
Dilution = 5 ml (sample dilution)
Label claim = 0.0001 (to convert the results in PPM.
[0202] The amount of 14-hydroxycodeinone (abbreviated as OHC) in oxycodone
sample
in ppm can be determined automatically from a linear calibration curve using
the two
standards (100 PPM and 10 PPM) and the equation used in the calculation below.
4 ¨Ymterce t
PPM of140HC¨ ____________________ X -1 )- x 1000000
Slope W sam
where:
Asan, = peak area of 140HC
Yintercept = Y intercept from a linear regression line using the two standards
Slope = slope from a linear regression line using the two standards
D = 5.0 (sample dilution factor)
= sample weight in mg
1000000 = Convention factor to convert the result to PPM
EXAMPLE 5
102031 3.0 g of oxycodone hydrochloric salt containing 154 ppm 14-
hydroxycodeinone
was dissolved in 20 mL water to afford a clear solution in a 250 mL Parr
reaction bottle.
To the solution, 0.05 g 5% Pd/C catalyst, 50% water wet (Johnson Matthey type
87L) and
1 mL formic acid 88% were added. The mixture was placed under inert atmosphere

without hydrogen feed and then heated to 45 C ¨ 50 C. After 2 hours of
shaking, a
51

CA 02557845 2010-07-23
sample was taken to check the disappearance of 14-hydroxycodeinone. The sample

showed no 14-hydroxycodeinone by the HPLC method described in Example 4 above.
[0204] The solution was then suction filtered over a 0.2 micron PTFE membrane
to
remove the catalyst. An aliquot of 2 mL was taken out of about 18 mL filtrate
solution.
To this solution, 2.0 mL isopropyl alcohol was added to obtain a clear
solution, followed
by 4.0 mL of ethyl acetate. The solution was stirred, cooled and kept at 0-5 C
for 20
hours to afford oxycodone hydrochloride crystals. The crystalline solid was
isolated by
suction filtration. The wet solid was dried in an oven at 50 C and 10 mmHg
pressure.
The dried solid weighed 0.12 g.
[0205] Analysis using the HPLC method in Example 4 above indicated that about
11
ppm 14-hydroxycodeinone were present in the oxycodone hydrochloride salt
composition. In another aliquot of 2 mL of the filtrate solution, 16-18 mL of
isopropyl
alcohol was added to the concentrated oxycodone hydrochloride solution
followed by
crystallization and drying. The procedure afforded oxycodone hydrochloride
salt
containing about 6.8 ppm 14-hydroxycodeinone.
EXAMPLE 6
[0206] Analysis of Sample to Determine 14-Hydroxycodeinone and Codeinone
[0207] The products of Examples 1-3 were analyzed by the following alternative
method
to determine the amount of codeinone and 14-hydroxycodeinone present. This
method
uses a Waters Symmetry C18 column maintained at 40 C with isocratic elution
using a
mobile phase of sodium phosphate buffer, sodium dodecyl sulfate (SDS),
acetonitrile
(ACN), and methanol (Me0H).
[0208] The reagents used were as follows:
1. Water, HPLC grade or equivalent;
2. Phosphoric acid, 85%, HPLC reagent grade or equivalent;
3. Sodium phosphate monobasic, monohydrate, Enzyme grade or equivalent;
4. Sodium dodecyl sulfate (99%+), Ultrapure, Fluka or equivalent;
52

CA 02557845 2010-07-23
5. Acetonitrile, HPLC grade or equivalent;
6. Methanol, HPLC grade or equivalent;
7. Sodium hydroxide, ACS reagent grade or equivalent;
8. Oxycodone HC1 with low ABUK to be used as part of the matrix in standard
preparation;
9. Codeinone reference material from Rhodes Technologies or equivalent;
10. 14-Hydroxycodeinone reference material from Albany Molecular Research or
equivalent
10209] The equipment used was as follows:
A. HPLC SYSTEM
For this analysis, an HPLC system with a dual wavelength detector was used
that was
able to operate under isocratic conditions at a flow rate of 0.7 mL per minute
with UV
detection @ 220 tun, and a column temperature of 40 C.
B. Mobile Phase Filtration System
For this analysis, an HPLC vacuum filtration apparatus with a nylon membrane
filter (0.45itm) was used.
Solutions
i. 50 % Sodium Hydroxide Solution (w/v)
50 g of sodium hydroxide pellets were weighed and transferred into a 100-mL
volumetric flask. 60-mL of water was then added and sonicated until the
pellets were
completely dissolved. The pellets were diluted to volume with water and mixed
well.
(Commercially available 50% w/v NaOH solution may also be used.)
53

CA 02557845 2010-07-23
ii. Phosphoric Acid Solution I (¨ 8.5% H3PO4)
ml of concentrated phosphoric acid (85%) was transferred into a 100 ml
volumetric
flask containing approximately 50 ml of water. The volume was diluted with
water and
then mixed.
iii. Phosphoric Acid Solution II (¨ 0.85% H3PO4)
10-mL of 85% phosphoric acid was pipetted into a 1000-mL volumetric flask,
diluted to
volume with water and mixed well. This was the diluent for the sample and
standard
preparation.
iv. Mobile Phase
3.45 g 0.1 g of sodium phosphate monobasic monohydrate was weighed into a 1-
L
flask. 1000 mL of water was added and then stirred with a magnetic stirrer
until
dissolved. 5.41 g 0.1 g of sodium dodecyl sulfate was added and mixed well
until
dissolved. This solution was filtered using vacuum filtration with a 0.45- m
nylon
membrane filter. The pH of this solution was adjusted with 50% NaOH solution
to a
final pH of 7.50 0.05.
722.5 ml of the above solution was then mixed with 157.5 mL of acetonitrile,
then 120
mL of methanol was added to the solutions and mixed well. The final pH was
adjusted to
7.80 0.01 with ¨ 8.5% phosphoric acid solution. The mobile phase was
sonicated for
about 5 minutes to remove dissolved air.
i. Standard Solution Preparation Calculated Relative To Dried Samples
A. Codeinone/14-Hydroxycodeinone Stock Solution I
25 1 mg of both codeinone and 14-hydroxycodeinone reference materials were
weighed
and transferred into a 100-mL volumetric flask, diluted to volume and
dissolved with ¨
0.85% phosphoric acid solution II.
54

CA 02557845 2010-07-23
100 ppm Stock Standard II
1-ml of stock solution I was pipetted into a 50-ml volumetric flask, diluted
to volume
with ¨0.85% phosphoric acid solution II and then mixed.
iii. 10 ppm working Standard III
500 5mg of Oxycodone low ABUK material was weighed into a 10-ml volumetric
flask. 1-ml of stock standard II was pipetted and diluted to volume with ¨
0.85%
phosphoric acid solution II and mixed.
iv. Unspiked Oxycodone solution
500 5mg of Oxycodone low ABUK material was weighed into a 10-ml volumetric
flask, diluted to volume with ¨ 0.85% phosphoric acid solution II and mixed.
(This
solution was used to calculate the residual content of both Codeinone and 14-
Hydroxycodeinone in the working standard).
E. Resolution Test Mixture (RTM)
1.0-ml of the Codeinone/14-Hydroxycodeinone stock solution I was pipetted into
a 50-ml
volumetric flask. Using a micropipette, 100 1 of the unspiked Oxycodone
solution was
transferred and diluted to volume with ¨ 0.85% phosphoric acid solution II.
The
concentration of Codeinone, 14-Hydroxycodeinone, and Oxycodone was
approximately
100 ppm.
F. Sample Preparations
i. 50 mg/mL Oxycodone HC1 Sample Solution
500 5mg of Oxycodone HC1 was weighed, in duplicate, into separate 10-mL
volumetric
flasks for each of Examples 1, 2 and 3. The Oxycodone HC1 was then diluted to
volume

4 õ
CA 02557845 2010-07-23
with the ¨ 0.85% phosphoric acid solution II and swirled to dissolve the
sample. A
sufficient amount of this sample was transferred to an HPLC vial for
injection.
G. HPLC Conditions
The HPLC conditions were set as follows:
TABLE 4. HPLC Conditions
Parameter Condition
HPLC Column Symmetry C18,3.0 x 150mm, 3.5 gm particle size
Mobile Phase 18 mM phosphate/13 mM SDS pH = 7.50: ACN:
Me0H (72.25:15.75:12.0) pH=7.80 0.01
Flow Rate* 0.7 mL/min
Column Temperature 40 C
Detection 220nm
Injection Volume 5 gL
= Run Time 50 minutes
1
* Parameter may be adjusted to achieve retention times.
H. System Suitability
One injection (5-4) of a blank solution (-0.85% phosphoric acid solution II)
was
made, followed by one injection of the RTM to determine if there was any
interfering
peaks in the blank solution. 6 injections of the working standard III were
made. The
system suitability injections were then tested to verify that they met the
system
suitability criteria as shown in Table 2.
56

CA 02557845 2010-07-23
TABLE 5 System Suitability Criteria
Parameter
Acceptance Criteria
Resolution between Codeinone and 14-Hydroxycodeinone NLT 8
Resolution between 14-Hydroxycodeinone and Oxycodone NLT 2
Tailing factor for Oxycodone 0.7-2.0
Relative retention times for Codeinone based on Oxycodone Approx. 0.44
Relative retention times for 14-Hydroxycodeinone based on
Approx. 0.85
Oxycodone
%RSD of 6 system suitability injections for Codeinone and
NMT 20%
14-Hydroxycodeinone
The expected retention times were as follows:
Components Expected Retention
Times
Codeinone 14 2 min
14-Hydroxycodeinone 27 4 min
Oxycodone 32 6 min
I. Injection Procedure
Once the column was equilibrated, the sample and standard solutions were
injected according to the following sequence of Table 3:
57

CA 02557845 2010-07-23
Table 6
Blank (diluent) 1 injection
Resolution solution 1 injection
Working Standard III 6 injections for RSD, last 2
injections for calibration
Blank (diluent) 2 injections
Unspiked Oxycodone solution 2 injections
Sample 1 Prep# 1 2 injections
Working Standard III 2 injections
Sample 1 Prep# 2 2 injections
Sample 2 Prep# 1 2 injections
Sample 2 Prep# 2 2 injections
Working Standard III 2 injections
Sample 3, Prep # 1 2 injections
Sample 3, Prep# 2 2 injections
Working Standard III 2 injections
The Codeinone and 14-Hydroxycodeinone peaks were identified using the
relative retention times as discussed above.
Calculations
[0210] The responses of Codeinone and 14-Hydroxycodeinone peaks were measured
and
recorded. The content of Codeinone and 14-Hydroxycodeinone was calculated in
ppm
using the following equation:
Rs x Wstd 1 1 1 10 1,000,000
PPm = x x x x x
Rstd x Ws 100 50 10 1 1
58

CA 02557845 2010-07-23
Rs x Wstd x 200
ppm
Rstd x Ws
Where:
ppm = Parts per millions of codeinone or 14-Hydroxycodeinone in
Oxycodone HCI
Rs= Response of Codeinone or 14-Hydroxycodeinone in Sample
Solution.
Rstd= Response of Codeinone or 14-Hydroxycodeinone in
Standard Solution minus the response of unspiked standard
Wstd= Weight of Standard, corrected for purity, mg
Ws= Weight of Sample, mg
1000000= Conversion Factor for ppm
% Codeinone/14-hydroxycodeinone = ppm / 10,000
102111 The results for Example 1 utilizing the procedure of Example 6 gave a
result of <
ppm of codeinone and 8 ppm of 14-hydroxycodeinone.
102121 The results for Example 2 utilizing the procedure of Example 6 gave a
result of <
5 ppm of codeinone and < 5 ppm of 14-hydroxycodeinone.
102131 The results for Example 3 utilizing the procedure of Example 6 gave a
result of <
5 ppm of codeinone and 10 ppm of 14-hydroxycodeinone.
10214] Many other variations of the present invention will be apparent to
those skilled in
the art and are meant to be within the scope of the claims appended hereto.
59

A single figure which represents the drawing illustrating the invention.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Admin Status

Title Date
Forecasted Issue Date 2013-10-01
(86) PCT Filing Date 2005-03-30
(87) PCT Publication Date 2005-10-20
(85) National Entry 2006-08-25
Examination Requested 2006-08-25
(45) Issued 2013-10-01

Abandonment History

Abandonment Date Reason Reinstatement Date
2012-10-05 FAILURE TO PAY FINAL FEE 2013-06-26

Maintenance Fee

Last Payment of $450.00 was received on 2020-02-21


 Upcoming maintenance fee amounts

Description Date Amount
Next Payment if small entity fee 2021-03-30 $229.50
Next Payment if standard fee 2021-03-30 $459.00

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Patent fees are adjusted on the 1st of January every year. The amounts above are the current amounts if received by December 31 of the current year. Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Request for Examination $800.00 2006-08-25
Application Fee $400.00 2006-08-25
Registration of a document - section 124 $100.00 2006-12-12
Maintenance Fee - Application - New Act 2 2007-03-30 $100.00 2007-03-02
Maintenance Fee - Application - New Act 3 2008-03-31 $100.00 2008-01-08
Maintenance Fee - Application - New Act 4 2009-03-30 $100.00 2008-12-30
Advance an application for a patent out of its routine order $500.00 2009-10-26
Maintenance Fee - Application - New Act 5 2010-03-30 $200.00 2010-01-07
Maintenance Fee - Application - New Act 6 2011-03-30 $200.00 2011-01-14
Maintenance Fee - Application - New Act 7 2012-03-30 $200.00 2011-12-22
Maintenance Fee - Application - New Act 8 2013-04-02 $200.00 2013-01-07
Reinstatement - Failure to pay final fee $200.00 2013-06-26
Final Fee $300.00 2013-06-26
Maintenance Fee - Patent - New Act 9 2014-03-31 $200.00 2014-02-17
Maintenance Fee - Patent - New Act 10 2015-03-30 $250.00 2015-02-12
Maintenance Fee - Patent - New Act 11 2016-03-30 $250.00 2016-02-10
Maintenance Fee - Patent - New Act 12 2017-03-30 $250.00 2017-02-14
Maintenance Fee - Patent - New Act 13 2018-04-03 $250.00 2018-02-21
Maintenance Fee - Patent - New Act 14 2019-04-01 $250.00 2019-02-21
Maintenance Fee - Patent - New Act 15 2020-03-30 $450.00 2020-02-21
Current owners on record shown in alphabetical order.
Current Owners on Record
EURO-CELTIQUE S.A.
Past owners on record shown in alphabetical order.
Past Owners on Record
CHAPMAN, ROBERT
HONG, QI
KUPPER, ROBERT
KYLE, DONALD
RIDER, LONN S.
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.

To view selected files, please enter reCAPTCHA code :




Filter

Document
Description
Date
(yyyy-mm-dd)
Number of pages Size of Image (KB)
Claims 2011-03-30 12 388
Claims 2006-08-25 10 423
Abstract 2006-08-25 2 67
Drawings 2006-08-25 5 51
Description 2006-08-25 53 3,020
Claims 2006-08-26 10 366
Representative Drawing 2006-10-26 1 11
Cover Page 2006-10-26 1 40
Claims 2007-05-30 11 437
Claims 2009-11-05 11 322
Description 2009-11-05 53 2,467
Claims 2010-07-23 12 402
Description 2010-07-23 59 2,754
Abstract 2010-07-23 1 8
Abstract 2013-07-26 1 8
Cover Page 2013-09-04 1 45
Prosecution-Amendment 2009-11-05 97 4,996
Assignment 2008-10-15 4 155
PCT 2006-08-25 1 57
Assignment 2006-08-25 4 110
Prosecution-Amendment 2006-08-25 11 401
Correspondence 2010-03-09 1 18
Correspondence 2010-02-05 3 84
Prosecution-Amendment 2010-03-05 3 137
Correspondence 2010-03-09 1 12
Prosecution-Amendment 2011-08-10 2 45
Correspondence 2006-10-19 1 28
Correspondence 2006-11-01 1 30
PCT 2006-08-25 1 45
Assignment 2006-12-12 6 157
Fees 2007-03-02 1 49
Prosecution-Amendment 2007-05-30 17 717
Prosecution-Amendment 2011-08-16 5 224
Fees 2008-01-08 1 54
Fees 2008-12-30 1 52
Prosecution-Amendment 2009-05-05 4 151
Prosecution-Amendment 2009-10-26 2 93
Prosecution-Amendment 2009-11-06 1 13
Prosecution-Amendment 2009-11-05 97 4,020
Fees 2010-01-07 1 58
Prosecution-Amendment 2010-07-23 167 7,430
Prosecution-Amendment 2010-09-30 3 152
Prosecution-Amendment 2011-03-30 33 1,357
Prosecution-Amendment 2011-06-15 2 49
Prosecution-Amendment 2011-11-16 13 708
Prosecution-Amendment 2011-12-02 5 311
Prosecution-Amendment 2013-02-08 3 85
Prosecution-Amendment 2012-04-10 6 268
Prosecution-Amendment 2012-05-31 2 47
Prosecution-Amendment 2012-08-23 2 46
Prosecution-Amendment 2013-01-15 1 19
Prosecution-Amendment 2013-06-26 1 48
Correspondence 2013-06-26 1 47
Correspondence 2013-06-26 2 51
Prosecution-Amendment 2013-07-26 1 20